N-acetyl-L-tryptophan : A N-acetyl-L-amino acid that is the N-acetyl derivative of L-tryptophan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
N-acetyltryptophan : An N-acetylamino acid that is the N-acetyl derivative of tryptophan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 700653 |
| CHEMBL ID | 54170 |
| CHEBI ID | 74640 |
| SCHEMBL ID | 57141 |
| MeSH ID | M0048924 |
| PubMed CID | 2002 |
| CHEMBL ID | 1905494 |
| CHEBI ID | 70976 |
| SCHEMBL ID | 57140 |
| MeSH ID | M0048924 |
| Synonym |
|---|
| acetyl-l-tryptophan |
| ac-try |
| 1218-34-4 |
| n-acetyl-l-tryptophan |
| u9264t8oae , |
| unii-u9264t8oae |
| bdbm50043821 |
| (s)-2-acetylamino-3-(1h-indol-3-yl)-propionic acid |
| (s)-2-acetamido-3-(1h-indol-3-yl)propanoic acid |
| AKOS015837748 |
| KBIO1_000385 |
| DIVK1C_000385 |
| SPECTRUM_000959 |
| tryptophan, n-acetyl-, l- |
| l-tryptophan, n-acetyl- |
| BSPBIO_003012 |
| NCGC00094838-01 |
| NCGC00094838-02 |
| (s)-n-acetyltryptophan |
| acetyl tryptophan |
| nsc 90726 |
| einecs 214-935-9 |
| acetyl-l-trp |
| KBIOGR_001241 |
| KBIO3_002232 |
| KBIO2_004007 |
| KBIOSS_001439 |
| KBIO2_001439 |
| KBIO2_006575 |
| SPECTRUM4_000551 |
| NINDS_000385 |
| SPBIO_001535 |
| SPECTRUM2_001348 |
| SPECTRUM3_001396 |
| SPECTRUM1500702 |
| IDI1_000385 |
| SPECTRUM5_001350 |
| NCGC00094838-03 |
| A-1820 |
| N-ACETYL-TRYPTOPHAN , |
| 38435FC5-4D99-4E9C-A55B-099BA6C5197C |
| ac-trp-oh |
| A0121 |
| CHEMBL54170 , |
| chebi:74640 , |
| HMS501D07 |
| HMS1921E12 |
| (2s)-2-acetamido-3-(1h-indol-3-yl)propanoic acid |
| AKOS010397427 |
| CCG-39286 |
| FD3078 |
| SCHEMBL57141 |
| n-|a-acetyl-l-tryptophan |
| AM82275 |
| acetyltryptophan, l- |
| l-acetyltryptophan |
| J-300263 |
| n-acetyltryptophan, european pharmacopoeia (ep) reference standard |
| AS-57887 |
| EN300-263728 |
| n-acetyl-l-tryptophan, pharmaceutical secondary standard; certified reference material |
| tryptophan, acetyl |
| ac-trp |
| Q27144794 |
| CS-W012694 |
| DTXSID10883669 |
| HY-W011978 |
| Z98653227 |
| nsc90726 |
| nsc-90726 |
| AC-19242 |
| CBDIVE_014228 |
| 2-acetamido-3-(1h-indol-3-yl)-propionic acid |
| tryptophan, n-acetyl-, dl- |
| d,l-.alpha.-acetylamino-3-indolepropionic acid |
| nsc-49124 |
| dl-acetyltryptophan |
| 87-32-1 |
| dl-tryptophan, n-acetyl- |
| n-acetyl-dl-tryptophan |
| n-acetyl-dl-tryptophane |
| dl-n-acetyltryptophan |
| NSC49124 , |
| NCI60_004180 |
| smr000339886 |
| MLS000686793 |
| OPREA1_817403 |
| acetyltryptophan |
| n-acetyltryptophan |
| ACON1_001308 |
| STK367673 |
| SR-01000597217-2 |
| NCIOPEN2_005595 |
| A-1810 |
| 3AD26BD1-C587-4301-9682-DA13678CE54F |
| tryptophan, n-acetyl- |
| ac-dl-trp-oh |
| A0120 |
| inchi=1/c13h14n2o3/c1-8(16)15-12(13(17)18)6-9-7-14-11-5-3-2-4-10(9)11/h2-5,7,12,14h,6h2,1h3,(h,15,16)(h,17,18) |
| dzthigrzjzprdv-uhfffaoysa- |
| BRD-A18626878-001-01-6 |
| 2-acetamido-3-(1h-indol-3-yl)propanoic acid |
| AKOS000120599 |
| A804795 |
| BBL000688 |
| 2-(acetylamino)-3-(1h-indol-3-yl)propanoic acid |
| n-acetyl-trp-oh |
| nsc 49124 |
| d,l-alpha-acetylamino-3-indolepropionic acid |
| 4460nbv53f , |
| einecs 201-739-3 |
| nalpha-acetyl-dl-tryptophan |
| unii-4460nbv53f |
| HMS2271L03 |
| A13889 |
| CCG-41706 |
| n-acetyl tryptophan |
| bdbm91686 |
| FT-0634178 |
| FT-0629814 |
| FT-0633493 |
| n-acetyltryptophane |
| CHEBI:70976 , |
| HMS3372O11 |
| n-acetyltryptophan [ep monograph] |
| acetyltryptophan [who-dd] |
| acetyltryptophan, dl- [ii] |
| acetyltryptophan, dl- |
| SCHEMBL57140 |
| AB00637124-07 |
| n-acetyl-d,l-tryptophan |
| n-acetyl dl-tryptophan |
| n-|a-acetyl-dl-tryptophan |
| AM82276 |
| AKOS016040255 |
| cambridge id 5117020 |
| J-300264 |
| CHEMBL1905494 |
| dl-.alpha.-acetylamino-3-indolepropionic acid |
| dl-.alpha.-acetamidoindole-3-propionic acid |
| acetyl-dl-tryptophan |
| n-acetyltryptophan # |
| AC-27041 |
| n-alpha-acetyl-dl-tryptophan |
| mfcd00005644 |
| mfcd00065976 |
| mfcd00065021 |
| sr-01000597217 |
| SR-01000597217-1 |
| SY036184 |
| Z85881713 |
| DTXSID40861672 |
| HY-W011982 |
| Q27139225 |
| SY036799 |
| VS-00668 |
| n-a-acetyltryptophan |
| EN300-18555 |
| CS-W012698 |
| 2-acetylamino-3-(1h-indol-3-yl)propionic acid |
| SY040644 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " This reaction may be of biological concern, as it supplies a mechanism for protein modifications with possible toxic effects in human tissues where ethanol is metabolized." | ( Tryptophan analogues form adducts by cooperative reaction with aldehydes and alcohols or with aldehydes alone: possible role in ethanol toxicity. Austin, JE; Fraenkel-Conrat, H, 1992) | 0.28 |
| "N-acetyl-tryptophan and L-methionine effectively reduce the oxidation of susceptible tryptophan and methionine residues in antibodies and are safe for use in parenteral biotherapeutic formulations." | ( Mitigation of Oxidation in Therapeutic Antibody Formulations: a Biochemical Efficacy and Safety Evaluation of N-Acetyl-Tryptophan and L-Methionine. Dion, MZ; Leiske, D; Salisbury, CM; Sharma, VK; Zuch de Zafra, CL, 2018) | 0.48 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| L-tryptophan derivative | A proteinogenic amino acid derivative resulting from reaction of L-tryptophan at the amino group or the carboxy group, or from the replacement of any hydrogen of L-tryptophan by a heteroatom. |
| N-acetyl-L-amino acid | An L-amino acid having an N-acetyl substituent. |
| N-acetyl-amino acid | An N-acyl-amino acid that has acetyl as the acyl group. |
| tryptophan derivative | An amino acid derivative resulting from reaction of tryptophan at the amino group or the carboxy group, or from the replacement of any hydrogen of tryptophan by a heteroatom. The definition normally excludes peptides containing tryptophan residues. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 35.4813 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 5.0119 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 7.9433 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 7.9433 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Stromelysin-1 | Homo sapiens (human) | IC50 (µMol) | 500.0000 | 0.0000 | 1.1484 | 10.0000 | AID208198 |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | IC50 (µMol) | 67.6020 | 0.1343 | 0.8646 | 2.1450 | AID588797 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| endopeptidase activity | Stromelysin-1 | Homo sapiens (human) |
| metalloendopeptidase activity | Stromelysin-1 | Homo sapiens (human) |
| serine-type endopeptidase activity | Stromelysin-1 | Homo sapiens (human) |
| protein binding | Stromelysin-1 | Homo sapiens (human) |
| peptidase activity | Stromelysin-1 | Homo sapiens (human) |
| metallopeptidase activity | Stromelysin-1 | Homo sapiens (human) |
| zinc ion binding | Stromelysin-1 | Homo sapiens (human) |
| catalytic activity | Tryptophanase | Escherichia coli K-12 |
| protein binding | Tryptophanase | Escherichia coli K-12 |
| tryptophanase activity | Tryptophanase | Escherichia coli K-12 |
| lyase activity | Tryptophanase | Escherichia coli K-12 |
| pyridoxal phosphate binding | Tryptophanase | Escherichia coli K-12 |
| potassium ion binding | Tryptophanase | Escherichia coli K-12 |
| identical protein binding | Tryptophanase | Escherichia coli K-12 |
| L-cysteine desulfhydrase activity | Tryptophanase | Escherichia coli K-12 |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Stromelysin-1 | Homo sapiens (human) |
| nucleus | Stromelysin-1 | Homo sapiens (human) |
| mitochondrion | Stromelysin-1 | Homo sapiens (human) |
| cytosol | Stromelysin-1 | Homo sapiens (human) |
| extracellular matrix | Stromelysin-1 | Homo sapiens (human) |
| extracellular space | Stromelysin-1 | Homo sapiens (human) |
| plasma membrane | Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) |
| plasma membrane | Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) |
| plasma membrane | Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) |
| cytoplasm | Tryptophanase | Escherichia coli K-12 |
| cytosol | Tryptophanase | Escherichia coli K-12 |
| membrane | Tryptophanase | Escherichia coli K-12 |
| protein-containing complex | Tryptophanase | Escherichia coli K-12 |
| cell pole | Tryptophanase | Escherichia coli K-12 |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1226026 | Activity of 0.1 uM recombinant human IDO assessed as compound consumption at 100 uM after 1 hr by fluorescence detection method relative to control | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3 | N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase. |
| AID500816 | Inhibition of nitrogen-starved wild type sigma1278b yeast Gap1-mediated amino acid uptake at 5 mM after 60 secs relative to L-citrulline | 2009 | Nature chemical biology, Jan, Volume: 5, Issue:1 | Transport and signaling via the amino acid binding site of the yeast Gap1 amino acid transceptor. |
| AID1226027 | Retention time of the compound by HPLC analysis | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3 | N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase. |
| AID681113 | TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes | 2001 | The Journal of biological chemistry, May-18, Volume: 276, Issue:20 | Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. |
| AID26797 | Partition coefficient (logP) | 1987 | Journal of medicinal chemistry, Oct, Volume: 30, Issue:10 | Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1226024 | Activity of 5 uM recombinant human IDO assessed as compound consumption at 1000 uM after 4 hrs by UV detection method relative to control | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3 | N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase. |
| AID681161 | TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes | 2002 | Genomics, Jan, Volume: 79, Issue:1 | The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. |
| AID1226025 | Activity of 0.5 uM recombinant human IDO assessed as compound consumption at 100 uM after 1 hr by fluorescence detection method relative to control | 2015 | ACS medicinal chemistry letters, Mar-12, Volume: 6, Issue:3 | N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase. |
| AID208198 | Inhibition of recombinant stromelysin catalytic domain (SCD) | 1994 | Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1 | A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors. |
| AID233318 | Bitter threshold value | 1987 | Journal of medicinal chemistry, Oct, Volume: 30, Issue:10 | Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1224817 | Assays to identify small molecules inhibitory for eIF4E expression | 2015 | Chemistry & biology, Jul-23, Volume: 22, Issue:7 | Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds. |
| AID1159537 | qHTS screening for TAG (triacylglycerol) accumulators in algae | 2017 | Plant physiology, Aug, Volume: 174, Issue:4 | Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID1799730 | Enzyme Inhibition Assay from Article 10.1080/14756360802187612: \\New tryptophanase inhibitors: towards prevention of bacterial biofilm formation.\\ | 2009 | Journal of enzyme inhibition and medicinal chemistry, Apr, Volume: 24, Issue:2 | New tryptophanase inhibitors: towards prevention of bacterial biofilm formation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 28 (28.87) | 18.7374 |
| 1990's | 7 (7.22) | 18.2507 |
| 2000's | 20 (20.62) | 29.6817 |
| 2010's | 36 (37.11) | 24.3611 |
| 2020's | 6 (6.19) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.99) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Trials | 1 (1.11%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Reviews | 1 (1.11%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| Other | 88 (97.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4. | 2.01 | 1 | 0 | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule |
| beta-alanine [no description available] | 2.01 | 1 | 0 | amino acid zwitterion; beta-amino acid | agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter |
| hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl. | 1.97 | 1 | 0 | N-acylglycine | human blood serum metabolite; uremic toxin |
| alanylalanine alanylalanine: RN given refers to (DL)-isomer | 1.97 | 1 | 0 | dipeptide | |
| alanine [no description available] | 1.97 | 1 | 0 | alpha-amino acid; amino acid zwitterion | fundamental metabolite |
| glycine [no description available] | 2.68 | 3 | 0 | alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical |
| pipecolic acid pipecolic acid: RN given refers to cpd without isomeric designation. pipecolic acid : A piperidinemonocarboxylic acid in which the carboxy group is located at position C-2.. pipecolate : A piperidinecarboxylate that is the conjugate base of pipecolic acid. | 2.05 | 1 | 0 | piperidinemonocarboxylic acid | |
| pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis. | 2.41 | 2 | 0 | 2-oxo monocarboxylic acid | cofactor; fundamental metabolite |
| taurine [no description available] | 2.05 | 1 | 0 | amino sulfonic acid; zwitterion | antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite |
| tryptamine [no description available] | 2.11 | 1 | 0 | aminoalkylindole; aralkylamino compound; indole alkaloid; tryptamines | human metabolite; mouse metabolite; plant metabolite |
| n-acetylphenylalanine N-acetylphenylalanine: RN given refers to (DL)-isomer. N-acetylphenylalanine : The N-acetyl derivative of phenylalanine. | 1.97 | 1 | 0 | N-acetyl-amino acid; phenylalanine derivative | antidepressant; metabolite |
| tyramine [no description available] | 2 | 1 | 0 | monoamine molecular messenger; primary amino compound; tyramines | EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter |
| thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions. | 2 | 1 | 0 | 2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine | antithyroid drug; human metabolite; mouse metabolite; thyroid hormone |
| cysteine [no description available] | 2.39 | 2 | 0 | cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite |
| triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism. | 2 | 1 | 0 | 2-halophenol; amino acid zwitterion; iodophenol; iodothyronine | human metabolite; mouse metabolite; thyroid hormone |
| alanine Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2. | 2 | 1 | 0 | alanine zwitterion; alanine; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid | EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; fundamental metabolite |
| serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group. | 2.69 | 3 | 0 | L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid. | 2.69 | 3 | 0 | aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; mouse metabolite; neurotransmitter |
| glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4. | 2.39 | 2 | 0 | amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| lysine Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine. | 2.92 | 4 | 0 | aspartate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; lysine; organic molecular entity; proteinogenic amino acid | algal metabolite; anticonvulsant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease | 2.41 | 2 | 0 | amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug |
| tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring. | 2.92 | 4 | 0 | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical |
| leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group. | 2.68 | 3 | 0 | amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite |
| 2-aminoisobutyric acid 2-aminoisobutyric acid: RN given refers to unlabeled cpd. 2-aminoisobutyric acid : A rare, non-protein amino acid and end-product of pyrimidine metabolism, excreted in urine and found in some antibiotics of fungal origin. With the exception of a few bacteria, it is non-metabolisable, and therefore used in bioassays. | 2.01 | 1 | 0 | 2,2-dialkylglycine zwitterion; 2,2-dialkylglycine | |
| methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4. | 2.39 | 2 | 0 | aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid | antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical |
| phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group. | 2.92 | 4 | 0 | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid | algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| ornithine Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5. | 1.97 | 1 | 0 | non-proteinogenic L-alpha-amino acid; ornithine | algal metabolite; hepatoprotective agent; mouse metabolite |
| asparagine Asparagine: A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed). asparagine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 2-amino-2-oxoethyl group. | 2.39 | 2 | 0 | amino acid zwitterion; asparagine; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3. | 2.92 | 4 | 0 | amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine. | 2.39 | 2 | 0 | L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| threonine Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group. | 2.69 | 3 | 0 | amino acid zwitterion; aspartate family amino acid; L-alpha-amino acid; proteinogenic amino acid; threonine | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3. | 3.26 | 6 | 0 | erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan | antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| isoleucine Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine. | 2 | 1 | 0 | aspartate family amino acid; isoleucine; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite |
| arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group. | 2.39 | 2 | 0 | arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical |
| D-tryptophan [no description available] | 2.4 | 2 | 0 | D-alpha-amino acid; tryptophan zwitterion; tryptophan | bacterial metabolite |
| indopan indopan: RN given refers to parent cpd without isomeric designation. alpha-methyltryptamine : A tryptamine derivative having a methyl substituent at the alpha-position. | 2.11 | 1 | 0 | tryptamines | |
| 3-methoxytyrosine 3-O-methyldopa : A L-tyrosine derivative that is the 3-methoxy derivative of L-dopa. | 2 | 1 | 0 | aromatic L-alpha-amino acid zwitterion; L-tyrosine derivative; monomethoxybenzene; non-proteinogenic L-alpha-amino acid | human metabolite |
| citrulline citrulline : The parent compound of the citrulline class consisting of ornithine having a carbamoyl group at the N(5)-position. | 2.05 | 1 | 0 | amino acid zwitterion; citrulline | Daphnia magna metabolite; EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; protective agent; Saccharomyces cerevisiae metabolite |
| glycyl-glycyl-glycine glycyl-glycyl-glycine : A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence. | 2.4 | 2 | 0 | tripeptide zwitterion; tripeptide | |
| glycylglycine [no description available] | 2.4 | 2 | 0 | dipeptide zwitterion; dipeptide | human metabolite |
| norleucine Norleucine: An unnatural amino acid that is used experimentally to study protein structure and function. It is structurally similar to METHIONINE, however it does not contain SULFUR.. L-norleucine : A non-proteinogenic L-alpha-amino acid comprising hexanoic acid carrying an amino group at C-2. It does not occur naturally. | 1.97 | 1 | 0 | 2-aminohexanoic acid; L-alpha-amino acid zwitterion; non-proteinogenic L-alpha-amino acid | |
| glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2. | 2.92 | 4 | 0 | glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical |
| methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring. | 2 | 1 | 0 | L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent |
| d-lactic acid (R)-lactic acid : An optically active form of lactic acid having (R)-configuration. | 2.41 | 2 | 0 | 2-hydroxypropanoic acid | Escherichia coli metabolite; human metabolite |
| norvaline norvaline: differs from valine in being 1 carbon longer instead of branched; RN given refers to (L)-isomer; structure. L-2-aminopentanoic acid : A 2-aminopentanoic acid that has S-configuration. | 1.97 | 1 | 0 | 2-aminopentanoic acid; L-alpha-amino acid zwitterion | bacterial metabolite; hypoglycemic agent; neuroprotective agent |
| n-acetyltyrosine N-acetyl-L-tyrosine : An N-acetyltyrosine in which the chiral centre has L configuration. | 2.69 | 3 | 0 | N-acetyltyrosine; N-acyl-L-tyrosine | biomarker; EC 2.1.1.4 (acetylserotonin O-methyltransferase) inhibitor; human urinary metabolite |
| ethyl tyrosine ester ethyl tyrosine ester: RN given refers to L-isomer. ethyl L-tyrosinate : An L-tyrosyl ester that is L-tyrosine in which the hydrogen of the carboxy group has been replaced by an ethyl group. | 1.97 | 1 | 0 | ethyl ester; L-tyrosyl ester | |
| leucyltyrosine leucyltyrosine: RN given refers to L-Tyr,L-Leu-isomer; RN for cpd without isomeric designation not avail 4/93 | 2.4 | 2 | 0 | dipeptide | metabolite |
| tyrosine methyl ester tyrosine methyl ester: RN given refers to (L)-isomer. methyl L-tyrosinate : An L-tyrosyl ester that is the methyl ester of L-tyrosine. | 2.68 | 3 | 0 | L-tyrosyl ester; methyl ester | |
| carbobenzoxyphenylalanine carbobenzoxyphenylalanine: RN given refers to (L-Phe)-isomer | 1.98 | 1 | 0 | ||
| leucyl-glycyl-glycine leucyl-glycyl-glycine: RN given refers to (L-Leu)-isomer. Leu-Gly-Gly : A tripeptide composed of one L-leucine and two glycine residues joined in sequence. | 2.4 | 2 | 0 | tripeptide | metabolite |
| acetylleucine [no description available] | 1.97 | 1 | 0 | L-leucine derivative; N-acetyl-L-amino acid | metabolite |
| D-serine [no description available] | 2 | 1 | 0 | D-alpha-amino acid; serine zwitterion; serine | Escherichia coli metabolite; human metabolite; NMDA receptor agonist |
| D-alanine [no description available] | 2 | 1 | 0 | alanine zwitterion; alanine; D-alpha-amino acid | EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor; Escherichia coli metabolite; human metabolite |
| D-tyrosine [no description available] | 2 | 1 | 0 | D-alpha-amino acid zwitterion; D-alpha-amino acid; tyrosine | Escherichia coli metabolite |
| phenylalanine [no description available] | 2.41 | 2 | 0 | D-alpha-amino acid zwitterion; D-alpha-amino acid; phenylalanine | |
| 2-(methylamino)isobutyric acid alpha-(methylamino)isobutyric acid : A non-proteinogenic alpha-amino acid that is isobutyric acid in which the alpha-hydrogen has been replaced by a methylamino group. | 2.01 | 1 | 0 | alanine derivative; alpha-amino acid zwitterion; non-proteinogenic alpha-amino acid; secondary amino compound | human urinary metabolite |
| leucylleucine Leu-Leu : A dipeptide formed from two L-leucine residues. | 2.4 | 2 | 0 | dipeptide; L-aminoacyl-L-amino acid zwitterion | human metabolite; Mycoplasma genitalium metabolite |
| phenylalanylleucine phenylalanylleucine: RN given refers to (L)-isomer | 1.97 | 1 | 0 | dipeptide zwitterion; dipeptide | plant metabolite |
| methyl tryptophan, (l-trp)-isomer [no description available] | 2.68 | 3 | 0 | ||
| leucyl-alanine Leu-Ala : A dipeptide composed of L-leucine and L-alanine joined by a peptide linkage. | 2.4 | 2 | 0 | dipeptide | metabolite |
| tryptophan ethyl ester tryptophan ethyl ester: RN given refers to (DL)-isomer | 1.97 | 1 | 0 | ||
| leucyl-leucyl-leucine leucyl-leucyl-leucine: RN given refers to (L-Leu-L-Leu-L-Leu)-isomer. Leu-Leu-Leu : A tripeptide formed from three L-leucine residues. | 2.4 | 2 | 0 | tripeptide | metabolite |
| tert-butyloxycarbonyltryptophan tert-butyloxycarbonyltryptophan: RN given refers to (L)-isomer | 2.42 | 2 | 0 | indolyl carboxylic acid | |
| tyrosylleucine [no description available] | 1.97 | 1 | 0 | dipeptide | metabolite |
| Trp-Trp tryptophyltryptophan: an antigelation agent. Trp-Trp : A dipeptide formed from two L-tryptophan residues. | 1.97 | 1 | 0 | dipeptide | Mycoplasma genitalium metabolite |
| glycyltryptophan glycyltryptophan: RN given refers to (L)-isomer. Gly-Trp : A dipeptide formed from glycine and L-tryptophan residues. | 2.4 | 2 | 0 | dipeptide | metabolite |
| glycyltyrosine Gly-Tyr : A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage. | 1.97 | 1 | 0 | dipeptide | metabolite |
| glycylleucine Gly-Leu : A dipeptide composed of glycine and L-leucine joined by a peptide linkage. | 2.4 | 2 | 0 | dipeptide zwitterion; dipeptide | metabolite |
| histidine methyl ester histidine methyl ester: RN given refers to (L)-isomer; structure given in first source. histidine methyl ester : An alpha-amino acid ester that is the methyl ester of histidine. | 1.97 | 1 | 0 | histidine derivative | |
| glycyl-l-phenylalanine glycylphenylalanine: RN given refers to (DL)-isomer. Gly-Phe : A dipeptide formed from glycine and L-phenylalanine residues. | 2.4 | 2 | 0 | dipeptide zwitterion; dipeptide | human metabolite; metabolite |
| droxidopa Droxidopa: A synthetic precursor of norepinephrine that is used in the treatment of PARKINSONIAN DISORDERS and ORTHOSTATIC HYPOTENSION.. droxidopa : A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension | 2 | 1 | 0 | catechols; L-tyrosine derivative | antihypertensive agent; prodrug; vasoconstrictor agent |
| aspartyl-phenylalanine aspartyl-phenylalanine: metabolite of aspartame; may inhibit angiotensin converting enzyme; RN given refers to all (L)-isomer | 2.05 | 1 | 0 | dipeptide | human blood serum metabolite; human xenobiotic metabolite |
| glycylsarcosine glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine. | 2.05 | 1 | 0 | dipeptide zwitterion; dipeptide | |
| n-acetylphenylalanine ethyl ester N-acetylphenylalanine ethyl ester: RN given refers to (L)-isomer | 1.97 | 1 | 0 | ||
| leucylleucine leucylleucine: RN given refers to (DL-Leu-DL-Leu)-isomer | 2.05 | 1 | 0 | peptide | |
| 2,2-dimethyl-beta-alanine [no description available] | 2 | 1 | 0 | ||
| alanylphenylalanine alanylphenylalanine: RN given refers to (L-Ala-L-PheAla)-isomer | 1.97 | 1 | 0 | dipeptide | metabolite |
| glycyl-leucyl-tyrosine glycyl-leucyl-tyrosine: structure given in first source | 2.4 | 2 | 0 | oligopeptide | |
| glycyl-glycyl-proline Gly-Gly-Pro : A tripeptide composed of glycine, glycine and L-proline amino acids joined in sequence by peptide linkages. | 2.05 | 1 | 0 | tripeptide zwitterion; tripeptide | |
| glycylaspartic acid glycylaspartic acid: RN given refers to (L)-isomer | 2.05 | 1 | 0 | dipeptide | metabolite |
| glycyl-histidyl-glycine [no description available] | 2.05 | 1 | 0 | oligopeptide | |
| n-glycylglutamic acid N-glycylglutamic acid: RN given refers to (L)-isomer. Gly-Glu : A dipeptide formed from glycyl and L-glutamic acid residues. | 2.05 | 1 | 0 | dipeptide | metabolite |
| benzyloxycarbonyltryptophan benzyloxycarbonyltryptophan: receptor antagonist for peptides from gastrin family; RN given refers to (L)-isomer | 1.98 | 1 | 0 | ||
| histidylglycine histidylglycine: RN given refers to all (L)-isomer. His-Gly : A dipeptide formed from L-histidine and glycine residues. | 2.05 | 1 | 0 | dipeptide | metabolite |
| valylvaline valylvaline: RN given refers to (L)-isomer. Val-Val : A dipeptide formed from two L-valine residues. | 2.4 | 2 | 0 | dipeptide | Mycoplasma genitalium metabolite |
| alpha-methylphenylalanine alpha-methylphenylalanine: induces chronic hyperphenylalaninemia in suckling rats; models for the study of inborn errors of metabolism; RN given refers to parent cpd without isomeric designation | 2.05 | 1 | 0 | benzenes; monocarboxylic acid | |
| prolinamide prolinamide: RN given refers to cpd without isomeric designation. L-prolinamide : The carboxamide derivative of L-proline. | 2.05 | 1 | 0 | amino acid amide; L-proline derivative; pyrrolidinecarboxamide | |
| 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid 2-aminobicyclo(2,2,1)heptane-2-carboxylic acid: amino acid analog; releases insulin; RN given refers to unlabeled cpd without isomeric designation | 2 | 1 | 0 | monoterpenoid | |
| tyrosyl-glycyl-glycine tyrosyl-glycyl-glycine: RN given refers to L-isomer; this may not be the same as IMREG-1. Tyr-Gly-Gly : A tripeptide composed of one L-tyrosine and two glycine residues joined in sequence. | 2.05 | 1 | 0 | tripeptide zwitterion; tripeptide | metabolite |
| proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2. | 2.69 | 3 | 0 | amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid | algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| arginylarginine 2-naphthylamide arginylarginine 2-naphthylamide: substrate for dipeptidyl peptidase III | 2.05 | 1 | 0 | ||
| histidylphenylalanine His-Phe : A dipeptide obtained by formal condensation of the carboxy group of L-histidine with the amino group of L-phenylalanine. | 2.05 | 1 | 0 | dipeptide | |
| prolyl-tyrosine prolyl-tyrosine: structure given in first source. Pro-Tyr : A dipeptide formed from L-proline and L-tyrosine residues. | 1.97 | 1 | 0 | dipeptide | metabolite |
| abrine abrine: from seeds of Abrus precatorius; structure in first source. N(alpha)-methyl-L-tryptophan : A N-methyl-L-alpha-amino acid that is the N(alpha)-methyl derivative of L-tryptophan. | 2.41 | 2 | 0 | L-tryptophan derivative; N-methyl-L-alpha-amino acid zwitterion; N-methyl-L-alpha-amino acid | Escherichia coli metabolite |
| kynurenine L-kynurenine : A kynurenine that has L configuration. | 2.11 | 1 | 0 | amino acid zwitterion; kynurenine; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| glycyl-glycyl-valine [no description available] | 2.05 | 1 | 0 | oligopeptide | |
| glycyl-glycyl-sarcosine glycyl-glycyl-sarcosine: structure given in first source | 2.05 | 1 | 0 | ||
| 5-hydroxytryptophan hydroxytryptophan : A hydroxy-amino acid that is tryptophan substituted by at least one hydroxy group at unspecified position.. 5-hydroxy-L-tryptophan : The L-enantiomer of 5-hydroxytryptophan. | 2.11 | 1 | 0 | 5-hydroxytryptophan; amino acid zwitterion; hydroxy-L-tryptophan; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; plant metabolite |
| cysteinylglycine cysteinylglycine: RN given refers to (L)-isomer; RN for cpd without isomeric designation not in Chemlne 7/13/83. L-cysteinylglycine : A dipeptide consisting of glycine having an L-cysteinyl attached to its alpha-amino group. It is an intermediate metabolite in glutathione metabolism. | 2.05 | 1 | 0 | dipeptide zwitterion; dipeptide | Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite |
| glutamyl-glutamic acid glutamyl-glutamic acid: RN given for (L,L)-isomer. Glu-Glu : A dipeptide composed of two L-glutamic acid units joined by a peptide linkage. | 2.05 | 1 | 0 | dipeptide | Mycoplasma genitalium metabolite |
| D-leucine [no description available] | 2 | 1 | 0 | D-alpha-amino acid zwitterion; D-alpha-amino acid; leucine | bacterial metabolite; Saccharomyces cerevisiae metabolite |
| n'-formylkynurenine N'-formylkynurenine: a photochemical breakdown product of tryptophan in proteins; RN given refers to parent cpd without isomeric designation | 2.11 | 1 | 0 | amino acid zwitterion; N-formylkynurenine; non-proteinogenic amino acid derivative; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| n-acetyl-d-tryptophan [no description available] | 1.98 | 1 | 0 | D-tryptophan derivative; N-acetyl-D-amino acid | |
| isoleucylvaline isoleucylvaline: RN given refers to all (L)-isomer. Ile-Val : A dipeptide formed from L-isoleucine and L-valine residues. | 1.97 | 1 | 0 | dipeptide | metabolite |
| Phe-Tyr Phe-Tyr : A dipeptide formed from L-phenylalanine and L-tyrosine residues. | 1.97 | 1 | 0 | dipeptide | metabolite |
| 1-methyltryptophan 1-methyltryptophan: an immunomodulator. 1-methyltryptophan : A tryptophan derivative that is tryptophan carrying a single methyl substituent at position 1 on the indole. | 2.11 | 1 | 0 | indolyl carboxylic acid | |
| n-benzoylalanine N-benzoylalanine: RN given refers to parent cpd (L-Ala)-isomer. N-benzoylalanine : An N-acylamino acid that is the N-benzoyl derivative of alanine.. N-benzoyl-L-alanine : An N-acyl-L-alanine resulting from the formal condensation of L-alanine with the carboxy group of benzoic acid. | 1.97 | 1 | 0 | N-acyl-L-alanine; N-benzoylalanine | metabolite |
| phenylalanine methyl ester phenylalanine methyl ester: RN given refers to (L)-isomer. methyl L-phenylalaninate : An alpha-amino acid ester that is the methyl ester of L-phenylalanine. | 2.68 | 3 | 0 | alpha-amino acid ester; L-phenylalanine derivative | |
| n-glycylalanine Gly-Ala : A dipeptide formed from glycine and L-alanine residues. | 2.05 | 1 | 0 | dipeptide | metabolite |
| glycylvaline glycylvaline: RN given refers to (DL)-isomer | 2.4 | 2 | 0 | dipeptide | human metabolite |
| epsilon-tert-butyloxycarbonyl-lysine epsilon-tert-butyloxycarbonyl-lysine: RN given refers to (L)-isomer | 2.05 | 1 | 0 | ||
| glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group. | 2.4 | 2 | 0 | dipeptide zwitterion; dipeptide | metabolite |
| prolylglycine prolylglycine: RN given refers to (L)-isomer. L-prolylglycine : A dipeptide consisting of glycine having an L-prolyl group attached to its alpha-amino nitrogen. | 1.97 | 1 | 0 | dipeptide zwitterion; dipeptide | |
| tryptophanol tryptophanol: RN given refers to cpd without isomeric designation | 2.05 | 1 | 0 | ||
| phenylalanylglycine phenylalanylglycine: RN given refers to (DL)-isomer. Phe-Gly : A dipeptide formed from L-phenylalanine and glycine residues. | 2.4 | 2 | 0 | dipeptide | metabolite |
| leucyl-phenylalanine Leu-Phe : A dipeptide formed from L-leucine and L-phenylalanine residues. | 1.97 | 1 | 0 | dipeptide | metabolite |
| glycyl-alanyl-phenylalanine [no description available] | 2.05 | 1 | 0 | oligopeptide | |
| glycyl-alanyl-leucine glycyl-alanyl-leucine: RN given refers to all (L)-isomer; RN for cpd without isomeric designation not avail 9/91 | 1.97 | 1 | 0 | peptide | |
| methionylglycine methionylglycine: RN given refers to (L)-isomer. Met-Gly : A dipeptide formed from L-methionine and glycine residues. | 2.05 | 1 | 0 | dipeptide | metabolite |
| phenylalanylphenylalanine Phe-Phe : A dipeptide formed from two L-phenylalanine residues. | 1.97 | 1 | 0 | dipeptide; L-aminoacyl-L-amino acid zwitterion | human blood serum metabolite; Mycoplasma genitalium metabolite |
| histidylhistidine histidylhistidine: RN given for L-,L-isomer | 2.05 | 1 | 0 | dipeptide | Mycoplasma genitalium metabolite |
| valylleucine valylleucine: RN given refers to all L-isomer. Val-Leu : A dipeptide formed from L-valine and L-leucine residues. | 2.4 | 2 | 0 | dipeptide | metabolite |
| alanylglycine [no description available] | 2.4 | 2 | 0 | dipeptide zwitterion; dipeptide | metabolite |
| alpha-glutamyltryptophan Trp-Glu : A dipeptide formed from L-tryptophan and L-glutamic acid residues. | 2.4 | 2 | 0 | dipeptide | metabolite |
| methionylglutamic acid Met-Glu : A dipeptide formed from L-methionine and L-glutamic acid residues. | 2.05 | 1 | 0 | dipeptide | metabolite |
| phenylalanylproline Phe-Pro : A dipeptide formed from L-phenylalanine and L-proline residues. | 1.97 | 1 | 0 | dipeptide | metabolite |
| prolylisoleucine prolylisoleucine: RN refers to (L)-isomer. Pro-Ile : A dipeptide formed from L-proline and L-isoleucine residues. | 1.97 | 1 | 0 | dipeptide | metabolite |
| phenylalanyl-valine phenylalanyl-valine: structure in first source. Phe-Val : A dipeptide formed from L-phenylalanine and L-valine residues. | 2.05 | 1 | 0 | dipeptide | metabolite |
| homocarnosine homocarnosine: RN given refers to parent cpd. homocarnosine : A histidine derivative that is histidine in which one of the hydrogens attached to the alpha-amino group has been replaced by a 4-aminobutanoyl group. | 2.05 | 1 | 0 | dipeptide zwitterion; dipeptide; homocarnosine; L-histidine derivative; N-acyl-L-alpha-amino acid anion; N-acyl-L-alpha-amino acid | human metabolite |
| clove Madagascar: One of the Indian Ocean Islands off the southeast coast of Africa. Its capital is Antananarivo. It was formerly called the Malagasy Republic. Discovered by the Portuguese in 1500, its history has been tied predominantly to the French, becoming a French protectorate in 1882, a French colony in 1896, and a territory within the French union in 1946. The Malagasy Republic was established in the French Community in 1958 but it achieved independence in 1960. Its name was changed to Madagascar in 1975. (From Webster's New Geographical Dictionary, 1988, p714) | 2.05 | 1 | 0 | ||
| 2-(3-pyridine)acetic acid 3-pyridylacetic acid : A monocarboxylic acid that is acetic acid substituted by a (pyridin-3-yl) group. It is a metabolite of nicotine and other tobacco alkaloids. | 2.11 | 1 | 0 | monocarboxylic acid; pyridines | human xenobiotic metabolite |
| gamma-aminobutyric acid gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4. | 2.21 | 1 | 0 | amino acid zwitterion; gamma-amino acid; monocarboxylic acid | human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule |
| 5-hydroxytryptophan 5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.. 5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5. | 2.35 | 2 | 0 | hydroxytryptophan | human metabolite; neurotransmitter |
| acetaldehyde Acetaldehyde: A colorless, flammable liquid used in the manufacture of acetic acid, perfumes, and flavors. It is also an intermediate in the metabolism of alcohol. It has a general narcotic action and also causes irritation of mucous membranes. Large doses may cause death from respiratory paralysis.. acetaldehyde : The aldehyde formed from acetic acid by reduction of the carboxy group. It is the most abundant carcinogen in tobacco smoke.. aldehyde : A compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.. acetyl group : A group, formally derived from acetic acid by dehydroxylation, which is fundamental to the biochemistry of all forms of life. When bound to coenzyme A, it is central to the metabolism of carbohydrates and fats. | 1.98 | 1 | 0 | aldehyde | carcinogenic agent; EC 3.5.1.4 (amidase) inhibitor; electron acceptor; Escherichia coli metabolite; human metabolite; mouse metabolite; mutagen; oxidising agent; Saccharomyces cerevisiae metabolite; teratogenic agent |
| butyric acid Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group. | 2.25 | 1 | 0 | fatty acid 4:0; straight-chain saturated fatty acid | human urinary metabolite; Mycoplasma genitalium metabolite |
| ureidosuccinic acid ureidosuccinic acid: RN given refers to (DL)-isomer. N-carbamoylaspartic acid : An N-carbamoylamino acid that is aspartic acid with one of its amino hydrogens replaced by a carbamoyl group. | 2.11 | 1 | 0 | aspartic acid derivative; C4-dicarboxylic acid; N-carbamoyl-amino acid | Escherichia coli metabolite; human metabolite; Saccharomyces cerevisiae metabolite |
| carnitine [no description available] | 2.25 | 1 | 0 | amino-acid betaine | human metabolite; mouse metabolite |
| levoplast Levoplast: mixture of acetamide, 2,2-dichloro-N-(2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl)-, (R-(R*,R*))-, castor oil, celluloidin, collodion & tannins | 2.15 | 1 | 0 | C-nitro compound | |
| chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion. | 2.42 | 2 | 0 | halide anion; monoatomic chlorine | cofactor; Escherichia coli metabolite; human metabolite |
| hydrochloric acid Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.. hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms. | 1.96 | 1 | 0 | chlorine molecular entity; gas molecular entity; hydrogen halide; mononuclear parent hydride | mouse metabolite |
| arabinofuranosylcytosine triphosphate [no description available] | 2.11 | 1 | 0 | pyrimidine ribonucleoside monophosphate | |
| aminoethylphosphonic acid Aminoethylphosphonic Acid: An organophosphorus compound isolated from human and animal tissues.. (2-aminoethyl)phosphonic acid : A phosphonic acid in which the hydrogen attached to the phosphorus of phosphonic acid is substituted by a 2-aminoethyl group. | 2.11 | 1 | 0 | phosphonic acids; primary amino compound; zwitterion | human metabolite; metabolite; mouse metabolite |
| octanoic acid octanoic acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #1764. octanoic acid : A straight-chain saturated fatty acid that is heptane in which one of the hydrogens of a terminal methyl group has been replaced by a carboxy group. Octanoic acid is also known as caprylic acid. | 3.26 | 6 | 0 | medium-chain fatty acid; straight-chain saturated fatty acid | antibacterial agent; Escherichia coli metabolite; human metabolite |
| hippuric acid hippuric acid: RN given refers to parent cpd; structure in Merck Index, 9th ed, #4591. N-benzoylglycine : An N-acylglycine in which the acyl group is specified as benzoyl. | 2.15 | 1 | 0 | N-acylglycine | human blood serum metabolite; uremic toxin |
| gamma-guanidinobutyric acid gamma-guanidinobutyric acid: RN given refers to parent cpd. 4-guanidinobutyric acid : A monocarboxylic acid that is butanoic acid substituted by a guanidino group at position 4.. 4-guanidinobutanoate : A monocarboxylic acid anion that is the conjugate base of 4-guanidinobutanoic acid.. 4-guanidinobutanoic acid : The 4-guanidino derivative of butanoic acid. | 2.11 | 1 | 0 | guanidines; monocarboxylic acid; zwitterion | fungal metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
| dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. | 1.96 | 1 | 0 | sulfoxide; volatile organic compound | alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger |
| glycine [no description available] | 7.13 | 1 | 0 | alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical |
| glycerol Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil. | 2 | 1 | 0 | alditol; triol | algal metabolite; detergent; Escherichia coli metabolite; geroprotector; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; solvent |
| indole [no description available] | 2.03 | 1 | 0 | indole; polycyclic heteroarene | Escherichia coli metabolite |
| indoleacetic acid indoleacetic acid: RN given refers to unlabeled parent cpd; structure in Merck Index, 9th ed, #4841. auxin : Any of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").. indole-3-acetic acid : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens has been replaced by a 1H-indol-3-yl group. | 1.98 | 1 | 0 | indole-3-acetic acids; monocarboxylic acid | auxin; human metabolite; mouse metabolite; plant hormone; plant metabolite |
| inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration. | 2.11 | 1 | 0 | cyclitol; hexol | |
| melatonin [no description available] | 2.03 | 1 | 0 | acetamides; tryptamines | anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger |
| n-acetylserotonin N-acetylserotonin : An N-acylserotonin resulting from the formal condensation of the primary amino group of serotonin with the carboxy group of acetic acid. | 6.96 | 1 | 0 | acetamides; N-acylserotonin; phenols | antioxidant; human metabolite; mouse metabolite; tropomyosin-related kinase B receptor agonist |
| nitrates Nitrates: Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. | 2.43 | 2 | 0 | monovalent inorganic anion; nitrogen oxoanion; reactive nitrogen species | |
| pentachlorophenol PENTA: structure given in first source | 2.11 | 1 | 0 | aromatic fungicide; chlorophenol; organochlorine pesticide; pentachlorobenzenes | human xenobiotic metabolite |
| phenylalanine [no description available] | 2.11 | 1 | 0 | alpha-amino acid; aromatic amino acid | Daphnia magna metabolite |
| putrescine [no description available] | 2.25 | 1 | 0 | alkane-alpha,omega-diamine | antioxidant; fundamental metabolite |
| spermidine [no description available] | 2.25 | 1 | 0 | polyazaalkane; triamine | autophagy inducer; fundamental metabolite; geroprotector |
| thymine [no description available] | 2.07 | 1 | 0 | pyrimidine nucleobase; pyrimidone | Escherichia coli metabolite; human metabolite; mouse metabolite |
| xanthine 7H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-7 is protonated.. 9H-xanthine : An oxopurine in which the purine ring is substituted by oxo groups at positions 2 and 6 and N-9 is protonated. | 2.15 | 1 | 0 | xanthine | Saccharomyces cerevisiae metabolite |
| atrolactic acid atrolactic acid: see also 3-isomer; RN given refers to parent cpd without isomeric designation; structure | 2.15 | 1 | 0 | 2-hydroxy monocarboxylic acid | |
| 2,2'-dipyridyl 2,2'-Dipyridyl: A reagent used for the determination of iron.. 2,2'-bipyridine : A bipyridine in which the two pyridine moieties are linked by a bond between positions C-2 and C-2'. | 2.04 | 1 | 0 | bipyridine | chelator; ferroptosis inhibitor |
| nsc-267703 [no description available] | 2.11 | 1 | 0 | anthracycline | |
| etofylline etofylline: etophyllin appeared once in PubMed: Wien Med Wochenschr. 1986 May 15;136(9):213-8 as a combination drug with theophylline (spelt without e, theophllin) | 2.15 | 1 | 0 | oxopurine | |
| 2,2'-azobis(2-amidinopropane) 2,2'-azobis(2-amidinopropane): water-soluble free-radical initiator | 2.17 | 1 | 0 | monoazo compound | |
| ethacridine Ethacridine: A topically applied anti-infective agent. | 2.15 | 1 | 0 | acridines | |
| tyrphostin ag957 tyrphostin AG957: tyrosine kinase blocker; structure given in first source | 2.11 | 1 | 0 | aromatic amine | |
| altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine. | 2.15 | 1 | 0 | triamino-1,3,5-triazine | |
| 2-amino-4-phosphonobutyric acid 2-amino-4-phosphonobutyric acid: glutamate antagonist in locust muscle; structure; do not confuse with L-AP4, which is the propionic acid version | 2.11 | 1 | 0 | ||
| aristolochic acid i aristolochic acid I: phospholipase A inhibitor. aristolochic acid A : An aristolochic acid that is phenanthrene-1-carboxylic acid that is substituted by a methylenedioxy group at the 3,4 positions, by a methoxy group at position 8, and by a nitro group at position 10. It is the most abundant of the aristolochic acids and is found in almost all Aristolochia (birthworts or pipevines) species. It has been tried in a number of treatments for inflammatory disorders, mainly in Chinese and folk medicine. However, there is concern over their use as aristolochic acid is both carcinogenic and nephrotoxic. | 2.11 | 1 | 0 | aristolochic acids; aromatic ether; C-nitro compound; cyclic acetal; monocarboxylic acid; organic heterotetracyclic compound | carcinogenic agent; metabolite; mutagen; nephrotoxin; toxin |
| benzamide benzamide : An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides. | 1.98 | 1 | 0 | benzamides | |
| benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication. | 2.11 | 1 | 0 | 1-benzofurans; aromatic ketone | uricosuric drug |
| benzylhydrochlorothiazide [no description available] | 2.11 | 1 | 0 | benzenes; benzothiadiazine; organochlorine compound; secondary amino compound; sulfonamide | |
| 2,5-di-tert-butylhydroquinone 2,5-di-tert-butylbenzene-1,4-diol : A member of the class of hydroquinones that is benzene-1,4-diol substituted by tert-butyl groups at position 2 and 5. | 2.15 | 1 | 0 | hydroquinones | |
| cetyltrimethylammonium ion Cetrimonium: Cetyltrimethylammonium compound whose salts and derivatives are used primarily as topical antiseptics.. cetyltrimethylammonium ion : A quaternary ammonium ion in which the substituents on nitrogen are one hexadecyl and three methyl groups. | 1.99 | 1 | 0 | quaternary ammonium ion | |
| eucalyptol [no description available] | 2.11 | 1 | 0 | ||
| amberlite cg 400 [no description available] | 2.11 | 1 | 0 | methyl ester; organic heteropentacyclic compound; yohimban alkaloid | |
| cx546 1-(1,4-benzodioxan-6-ylcarbonyl)piperidine: structure in first source | 2.15 | 1 | 0 | ||
| diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration. | 2.15 | 1 | 0 | ether; tertiary amino compound | anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative |
| stallimycin [no description available] | 2.11 | 1 | 0 | ||
| diuron Diuron: A pre-emergent herbicide.. diuron : A member of the class of 3-(3,4-substituted-phenyl)-1,1-dimethylureas that is urea in which both of the hydrogens attached to one nitrogen are substituted by methyl groups, and one of the hydrogens attached to the other nitrogen is substituted by a 3,4-dichlorophenyl group. | 2.15 | 1 | 0 | 3-(3,4-substituted-phenyl)-1,1-dimethylurea; dichlorobenzene | environmental contaminant; mitochondrial respiratory-chain inhibitor; photosystem-II inhibitor; urea herbicide; xenobiotic |
| domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations. | 2.11 | 1 | 0 | benzimidazoles; heteroarylpiperidine | antiemetic; dopaminergic antagonist |
| ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11. | 2.11 | 1 | 0 | indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene | antineoplastic agent; plant metabolite |
| glyphosate glyphosate: active cpd in herbicidal formulation Roundup; inhibits EC 2.5.1.19, 5-enolpyruvylshikimate-3-phosphate synthase; structure. glyphosate : A phosphonic acid resulting from the formal oxidative coupling of the methyl group of methylphosphonic acid with the amino group of glycine. It is one of the most commonly used herbicides worldwide, and the only one to target the enzyme 5-enolpyruvyl-3-shikimate phosphate synthase (EPSPS). | 2.11 | 1 | 0 | glycine derivative; phosphonic acid | agrochemical; EC 2.5.1.19 (3-phosphoshikimate 1-carboxyvinyltransferase) inhibitor; herbicide |
| haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. | 2.11 | 1 | 0 | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
| miltefosine miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin. miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine. | 2.11 | 1 | 0 | phosphocholines; phospholipid | anti-inflammatory agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antiprotozoal drug; apoptosis inducer; immunomodulator; protein kinase inhibitor |
| hypericin [no description available] | 2.11 | 1 | 0 | ||
| ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine | 2.15 | 1 | 0 | monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic |
| batyl alcohol batyl alcohol: RN given refers to cpd without isomeric designation. batilol : An alkylglycerol that is glycerol in which one of the primary hydroxy groups has been converted into the corresponding octadecyl ether. It is used in cosmetics as a stabilising ingredient and skin-conditioning agent. | 2.11 | 1 | 0 | alkylglycerol | |
| imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. | 2.11 | 1 | 0 | dibenzoazepine | adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor |
| ipriflavone ipriflavone : A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. | 2.15 | 1 | 0 | aromatic ether; isoflavones | bone density conservation agent |
| nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta). | 2.11 | 1 | 0 | indolobenzazepine; lactam; organobromine compound | cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector |
| ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively. | 2.11 | 1 | 0 | dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine | |
| khellin Khellin: A vasodilator that also has bronchodilatory action. It has been employed in the treatment of angina pectoris, in the treatment of asthma, and in conjunction with ultraviolet light A, has been tried in the treatment of vitiligo. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1024). khellin : A furanochrome in which the basic tricyclic skeleton is substituted at positions 4 and 9 with methoxy groups and at position 7 with a methyl group. A major constituent of the plant Ammi visnaga it is a herbal folk medicine used for various illnesses, its main effect being as a vasodilator. | 2.11 | 1 | 0 | furanochromone; organic heterotricyclic compound; oxacycle | anti-asthmatic agent; bronchodilator agent; cardiovascular drug; vasodilator agent |
| kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4. | 2.15 | 1 | 0 | monohydroxyquinoline; quinolinemonocarboxylic acid | G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite |
| 2-amino-3-phosphonopropionic acid 2-amino-3-phosphonopropionic acid: metabotropic glutamate receptor antagonist; do not confuse AP-3 used as an abbreviation for this with enhancer-binding protein AP-3 (a trans-activator) or clathrin assembly protein AP-3. 2-amino-3-phosphonopropanoic acid : A non-proteinogenc alpha-amino acid that is alanine in which one of the hydrogens of the terminal methyl group has been replaced by a dihydroxy(oxido)-lambda(5)-phosphanyl group. | 2.11 | 1 | 0 | alanine derivative; non-proteinogenic alpha-amino acid; phosphonic acids | human metabolite; metabotropic glutamate receptor antagonist |
| benzylsuccinic acid benzylsuccinic acid: inhibitor of carboxypeptidase A. 2-benzylsuccinic acid : A dicarboxylic acid consisting of succinic acid carrying a 2-benzyl substituent. | 2.11 | 1 | 0 | dicarboxylic acid | bacterial xenobiotic metabolite |
| beta-lapachone beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities. | 2.11 | 1 | 0 | benzochromenone; orthoquinones | anti-inflammatory agent; antineoplastic agent; plant metabolite |
| mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5. | 2.15 | 1 | 0 | aromatic ketone; benzimidazoles; carbamate ester | antinematodal drug; microtubule-destabilising agent; tubulin modulator |
| mesoridazine Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group. | 2.11 | 1 | 0 | phenothiazines; sulfoxide; tertiary amino compound | dopaminergic antagonist; first generation antipsychotic |
| methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis. | 2.11 | 1 | 0 | aromatic ether; psoralens | antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite |
| nocodazole [no description available] | 2.15 | 1 | 0 | aromatic ketone; benzimidazoles; carbamate ester; thiophenes | antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator |
| oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis. | 2.11 | 1 | 0 | 1,3-oxazoles; monocarboxylic acid | analgesic; non-steroidal anti-inflammatory drug |
| oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease). | 2.49 | 2 | 0 | benzenetriol; catecholamine; primary amino compound | drug metabolite; human metabolite; neurotoxin |
| quinone benzoquinone : The simplest members of the class of benzoquinones, consisting of cyclohexadiene which is substituted by two oxo groups.. 1,4-benzoquinone : The simplest member of the class of 1,4-benzoquinones, obtained by the formal oxidation of hydroquinone to the corresponding diketone. It is a metabolite of benzene.. quinone : Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included). | 2.03 | 1 | 0 | 1,4-benzoquinones | cofactor; human xenobiotic metabolite; mouse metabolite |
| penicillamine [no description available] | 2.11 | 1 | 0 | non-proteinogenic alpha-amino acid; thiol | |
| pentoxifylline [no description available] | 2.11 | 1 | 0 | oxopurine | |
| phenolsulfonphthalein Phenolsulfonphthalein: Red dye, pH indicator, and diagnostic aid for determination of renal function. It is used also for studies of the gastrointestinal and other systems.. phenol red : 3H-2,1-Benzoxathiole 1,1-dioxide in which both of the hydrogens at position 3 have been substituted by 4-hydroxyphenyl groups. A pH indicator changing colour from yellow below pH 6.8 to bright pink above pH 8.2, it is commonly used as an indicator in cell cultures and in home swimming pool test kits. It is also used in the (now infrequently performed) phenolsulfonphthalein (PSP) test for estimation of overall blood flow through the kidney. | 2.11 | 1 | 0 | 2,1-benzoxathiole; arenesulfonate ester; phenols; sultone | acid-base indicator; diagnostic agent; two-colour indicator |
| Picrotin, analytical standard [no description available] | 2.11 | 1 | 0 | furopyran | |
| piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist. | 2.15 | 1 | 0 | N-arylpiperazine | |
| pomiferin pomiferin: structure in first source | 2.11 | 1 | 0 | isoflavanones | |
| pridinol pridinol: antispasmodic & muscle relaxant; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7539. pridinol : A piperidine substituted at position 1 by a 3-hydroxy-3,3-diphenylpropyl group. | 2.11 | 1 | 0 | piperidines; tertiary alcohol | antiparkinson drug; muscle relaxant |
| procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. | 2.15 | 1 | 0 | benzamides | anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker |
| prometone prometone: structure. prometon : A methoxy-1,3,5-triazine that is 6-methoxy-1,3,5-triazine-2,4-diamine in which the one of the hydrogens of each amino group is substituted by an isopropyl group. | 2.15 | 1 | 0 | diamino-1,3,5-triazine; methoxy-1,3,5-triazine | environmental contaminant; herbicide; xenobiotic |
| propanil Propanil: A chlorinated anilide that is used as an herbicide.. propanil : An anilide resulting from the formal condensation of the carboxy group of propanoic acid with the amino group of 3,4-dichloroaniline. It is a herbicide used for the treatment of numerous grasses and broad-leaved weeds in rice, potatoes, and wheat. | 2.15 | 1 | 0 | anilide; dichlorobenzene | herbicide |
| sulfadimethoxine Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent.. sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. | 2.15 | 1 | 0 | aromatic ether; pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide | antiinfective agent; antimicrobial agent; drug allergen; environmental contaminant; xenobiotic |
| sulfamethazine Sulfamethazine: A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.. sulfamethazine : A sulfonamide consisting of pyrimidine with methyl substituents at the 4- and 6-positions and a 4-aminobenzenesulfonamido group at the 2-position. | 2.15 | 1 | 0 | pyrimidines; sulfonamide antibiotic; sulfonamide | antibacterial drug; antiinfective agent; antimicrobial agent; carcinogenic agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; ligand; xenobiotic |
| sulfaquinoxaline Sulfaquinoxaline: An antiprotozoal agent used to combat coccidial infections of swine, cattle, fowl, and other veterinary animals. Also used in controlling outbreaks of fowl typhoid and fowl cholera and in treatment of infectious enteritis. | 2.11 | 1 | 0 | benzenes; sulfonamide | |
| sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position. | 2.15 | 1 | 0 | 1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide | antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic |
| suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years. | 2.11 | 1 | 0 | naphthalenesulfonic acid; phenylureas; secondary carboxamide | angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug |
| 4-methylglutamic acid 4-methylglutamic acid : A glutamic acid derivative that is glutamic acid substituted by a methyl group at position 4. | 2.11 | 1 | 0 | amino dicarboxylic acid; glutamic acid derivative | |
| testosterone [no description available] | 2.15 | 1 | 0 | 3-hydroxy steroid | androgen |
| 2-hydroxybenzylbenzimidazole 2-hydroxybenzylbenzimidazole: RN given refers to cpd without isomeric designation | 2.15 | 1 | 0 | ||
| bromouracil Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen. | 2 | 1 | 0 | nucleobase analogue; pyrimidines | mutagen |
| pilocarpine hydrochloride pilocarpine hydrochloride : The hydrochloride salt of (+)-pilocarpine, a medication used to treat increased pressure inside the eye and dry mouth. | 2.11 | 1 | 0 | hydrochloride | |
| uridine [no description available] | 2 | 1 | 0 | uridines | drug metabolite; fundamental metabolite; human metabolite |
| levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease | 2.1 | 1 | 0 | amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug |
| tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring. | 8.39 | 7 | 0 | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical |
| veratramine veratramine: structure. veratramine : A piperidine alkaloid comprising the 14,15,16,17-tetradehydro derivative of veratraman having two hydroxy groups at the 3- and 23-positions. | 2.11 | 1 | 0 | piperidine alkaloid | |
| methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4. | 8.51 | 8 | 0 | aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid | antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical |
| phenylalanine Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group. | 1.97 | 1 | 0 | amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; phenylalanine; proteinogenic amino acid | algal metabolite; EC 3.1.3.1 (alkaline phosphatase) inhibitor; Escherichia coli metabolite; human xenobiotic metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| etimizol Etimizol: A xanthine-related, putative nootropic drug. | 2.15 | 1 | 0 | ||
| histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3. | 2.67 | 3 | 0 | amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid | algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite |
| tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3. | 7.03 | 76 | 1 | erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan | antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite |
| nifenalol nifenalol: adrenergic beta-blocker with good antiarrhythmic properties; also tends to lower blood pressure & provide protection against angina; minor descriptor (75-86); on-line & INDEX MEDICUS search ETHANOLAMINES (75-86); RN given refers to parent cpd without isomeric designation | 2.15 | 1 | 0 | C-nitro compound | |
| acetonitrile acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group. | 2.07 | 1 | 0 | aliphatic nitrile; volatile organic compound | EC 3.5.1.4 (amidase) inhibitor; NMR chemical shift reference compound; polar aprotic solvent |
| gibberellic acid gibberellic acid: RN given refers to (1alpha,2beta,4aalpha,4bbeta,10beta)-isomer; structure. gibberellin A3 : A C19-gibberellin that is a pentacyclic diterpenoid responsible for promoting growth and elongation of cells in plants. Initially identified in Gibberella fujikuroi,it differs from gibberellin A1 in the presence of a double bond between C-3 and C-4. | 2.11 | 1 | 0 | C19-gibberellin; gibberellin monocarboxylic acid; lactone; organic heteropentacyclic compound | mouse metabolite; plant metabolite |
| bis(4-hydroxyphenyl)sulfone bis(4-hydroxyphenyl)sulfone: structure and RN in first source. 4,4'-sulfonyldiphenol : A sulfone that is diphenyl sulfone in which both of the para hydrogens have been replaced by hydroxy groups. | 2.15 | 1 | 0 | bisphenol; sulfone | endocrine disruptor; metabolite |
| 9,10-anthraquinone 9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls. | 2.03 | 1 | 0 | anthraquinone | |
| 8-hydroxyquinoline-5-sulfonic acid 8-hydroxyquinoline-5-sulfonic acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| santowhite powder 4,4'-butylidenebis(6-tert-butyl-m-cresol): putatively both an androgen and estrogen antagonist; structure in first source | 2.11 | 1 | 0 | ||
| salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide. | 2.15 | 1 | 0 | benzanilide fungicide; salicylamides; salicylanilides | |
| 2-phenylbutyric acid 2-phenylbutyric acid : A monocarboxylic acid that is butyric acid substituted by a phenyl group at position 2. | 2.15 | 1 | 0 | benzenes; monocarboxylic acid | human xenobiotic metabolite |
| 4,4'-dimethoxybenzophenone 4,4'-dimethoxybenzophenone: structure in first source | 2.15 | 1 | 0 | ||
| quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4. | 2.13 | 1 | 0 | mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene | |
| quinoline [no description available] | 2.1 | 1 | 0 | azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinolines | |
| 6-phenyl-1,3,5-triazine-2,4-diamine 6-phenyl-1,3,5-triazine-2,4-diamine: structure in first source | 2.15 | 1 | 0 | ||
| proflavine Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds. | 2.08 | 1 | 0 | aminoacridines | antibacterial agent; antiseptic drug; carcinogenic agent; chromophore; intercalator |
| quinaldic acid [no description available] | 2.15 | 1 | 0 | quinolinemonocarboxylic acid | human metabolite; Saccharomyces cerevisiae metabolite |
| N-(2-methoxyphenyl)acetamide [no description available] | 2.15 | 1 | 0 | acetamides; methoxybenzenes | |
| benzothiazole benzothiazole: structure. benzothiazole : An organic heterobicyclic compound that is a fusion product between benzene and thiazole. The parent of the class of benzothiazoles. | 2.1 | 1 | 0 | benzothiazoles | environmental contaminant; plant metabolite; xenobiotic |
| fentichlor fentichlor: structure. fenticlor : An aryl sulfide having two 5-chloro-2-hydroxyphenyl groups attached to sulfur; an antiinfective drug mostly used in veterinary medicine. | 2.11 | 1 | 0 | aryl sulfide; bridged diphenyl antifungal drug; monochlorobenzenes; polyphenol | antiinfective agent; drug allergen |
| fast red b Fast Red B: structure in first source. fast red B : An organosulfonate salt composed from 2-methoxy-4-nitrobenzene-1-diazonium and 5-sulfonaphthalene-1-sulfonate in a 1:1 ratio. Used for demostrating enterochromaffin in carcinoid tumours. | 2.15 | 1 | 0 | ||
| pyrrolidonecarboxylic acid Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration. | 2.55 | 2 | 0 | 5-oxoproline; L-proline derivative; non-proteinogenic L-alpha-amino acid | algal metabolite |
| sym-trinitrobenzene Trinitrobenzenes: Benzene derivatives which are substituted with three nitro groups in any position.. 1,3,5-trinitrobenzene : A trinitrobenzene in which each of the nitro groups is meta- to the other two. | 1.98 | 1 | 0 | trinitrobenzene | explosive |
| methylenebis(chloroaniline) Methylenebis(chloroaniline): Aromatic diamine used in the plastics industry as curing agent for epoxy resins and urethane rubbers. It causes bladder, liver, lung, and other neoplasms.. 4,4'-methylene-bis-(2-chloroaniline) : A chloroaniline that consists of two 2-chloroaniline units joined by a methylene bridge. | 2.15 | 1 | 0 | chloroaniline | metabolite |
| di-(4-aminophenyl)ether di-(4-aminophenyl)ether: structure | 2.15 | 1 | 0 | aromatic ether | |
| diphenylguanidine diphenylguanidine: vulcanization accelerator; RN given refers to parent cpd. 1,3-diphenylguanidine : Guanidine carrying a phenyl substituent on each of the two amino groups. It is used as an accelerator in the rubber industry. | 2.15 | 1 | 0 | guanidines | allergen |
| 4-Anilino-4-oxobutanoic acid [no description available] | 2.15 | 1 | 0 | anilide | |
| hexadecanolide hexadecanolide: structure in first source | 2.11 | 1 | 0 | macrolide | |
| mephobarbital Mephobarbital: A barbiturate that is metabolized to PHENOBARBITAL. It has been used for similar purposes, especially in EPILEPSY, but there is no evidence mephobarbital offers any advantage over PHENOBARBITAL.. mephobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by ethyl and phenyl groups. | 2.15 | 1 | 0 | barbiturates | anticonvulsant |
| etryptamine etryptamine: RN given refers to cpd without isomeric designation | 2.15 | 1 | 0 | indoles | |
| sulfacetamide [no description available] | 2.15 | 1 | 0 | ||
| 1,4-naphthoquinone naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties. | 2.03 | 1 | 0 | 1,4-naphthoquinones | |
| pamoic acid pamoic acid: RN given refers to parent cpd; structure | 2.11 | 1 | 0 | dicarboxylic acid | |
| cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94 | 2.15 | 1 | 0 | quinolines | |
| 2-aminobenzothiazole [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| carzenide [no description available] | 2.53 | 2 | 0 | sulfonamide | |
| nitrilotriacetic acid Nitrilotriacetic Acid: A derivative of acetic acid, N(CH2COOH)3. It is a complexing (sequestering) agent that forms stable complexes with Zn2+. (From Miall's Dictionary of Chemistry, 5th ed.) | 2.15 | 1 | 0 | NTA; tricarboxylic acid | carcinogenic agent; nephrotoxic agent |
| cyacetacide cyacetacide: structure | 1.98 | 1 | 0 | ||
| n-(2-cyanoethyl)-2-phenylethylamine N-(2-cyanoethyl)-2-phenylethylamine: prodrug of 2-phenylethylamine | 2.15 | 1 | 0 | ||
| cyclooctane [no description available] | 2.15 | 1 | 0 | ||
| triphenyltetrazolium chloride 2,3,5-triphenyltetrazolium chloride : An organic chloride salt having 2,3,5-triphenyltetrazolium as the counterion. | 2.15 | 1 | 0 | organic chloride salt | dye; indicator |
| hydrazine diamine : Any polyamine that contains two amino groups. | 1.98 | 1 | 0 | azane; hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor |
| 2,7-diacetylaminofluorene 2,7-diacetylaminofluorene: has been found to induce leukemia in animals; minor descriptor (75-84); on-line search 2-ACETYLAMINOFLUORENE/AA (75-84); Index Medicus search 2-ACETYLAMINOFLUORENE/AA (80-82), FLUORENES (75-79) | 2.15 | 1 | 0 | ||
| estradiol 17 beta-cypionate [no description available] | 2.11 | 1 | 0 | steroid ester | |
| lithocholic acid Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid. | 2.11 | 1 | 0 | bile acid; C24-steroid; monohydroxy-5beta-cholanic acid | geroprotector; human metabolite; mouse metabolite |
| jervine jervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structure | 2.11 | 1 | 0 | piperidines | |
| bicuculline Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species. | 2.11 | 1 | 0 | benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines | agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin |
| salicylurate salicylurate: RN given refers to parent cpd. salicyluric acid : An N-acylglycine in which the acyl group is specified as 2-hydroxybenzoyl.. salicylurate : A monocarboxylic acid anion that is the conjugate base of salicyluric acid, obtained by deprotonation of the carboxy group; major species at pH 7.3. | 2.11 | 1 | 0 | N-acylglycine; secondary carboxamide | human xenobiotic metabolite; uremic toxin |
| 3,4-pyridinedicarboxylic acid 3,4-pyridinedicarboxylic acid: structure in first source | 2.15 | 1 | 0 | pyridinedicarboxylic acid | |
| 3,5-pyridinedicarboxylic acid 3,5-pyridinedicarboxylic acid: structure in first source | 2.11 | 1 | 0 | pyridinedicarboxylic acid | |
| ricinine [no description available] | 2.11 | 1 | 0 | nitrile; pyridine alkaloid; pyridone | |
| 4-(benzoylamino)-2-hydroxybenzoic acid 4-(benzoylamino)-2-hydroxybenzoic acid: Bepask is calcium salt | 2.15 | 1 | 0 | benzamides | |
| tropic acid tropic acid: acid moiety of ester alkaloids hyoscyamine & scopolamine; RN given refers to parent cpd with unspecified isomeric designation; structure. tropic acid : A 3-hydroxy monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a phenyl group, and one of the methyl hydrogens is substituted by a hydroxy group. | 2.15 | 1 | 0 | 3-hydroxy monocarboxylic acid | human xenobiotic metabolite |
| carinamide [no description available] | 2.11 | 1 | 0 | ||
| 3,5-dibromotyrosine 3,5-dibromotyrosine: used to synthesize various secondary metabolites from marine sponges | 2.11 | 1 | 0 | monocarboxylic acid | |
| 8-hydroxy-7-iodo-5-quinolinesulfonic acid 8-hydroxy-7-iodo-5-quinolinesulfonic acid: used with iodine isotopes in radioisotope scanning; structure | 2.15 | 1 | 0 | hydroxyquinoline | |
| hematoporphyrin Hematoporphyrins: Iron-free derivatives of heme with 4 methyl groups, 2 hydroxyethyl groups and 2 propionic acid groups attached to the pyrrole rings. Some of these PHOTOSENSITIZING AGENTS are used in the PHOTOTHERAPY of malignant NEOPLASMS.. hematoporphyrin : A dicarboxylic acid that is protoporphyrin in which the vinyl groups at positions 7 and 12 are replaced by 1-hydroxyethyl groups. | 2.11 | 1 | 0 | ||
| 1-acetylisatin 1-acetylisatin: structure in first source | 2.15 | 1 | 0 | indoledione | |
| docusate Dioctyl Sulfosuccinic Acid: All-purpose surfactant, wetting agent, and solubilizer used in the drug, cosmetics, and food industries. It has also been used in laxatives and as cerumenolytics. It is usually administered as either the calcium, potassium, or sodium salt. | 2 | 1 | 0 | diester; organosulfonic acid | |
| 2-benzoquinone 2-benzoquinone: reacts with methionines of RNAase at pH 1; reagent for determining conformational differences in related proteins. 1,2-benzoquinone : A benzoquinone resulting from the formal oxidation of catechol. | 1.96 | 1 | 0 | 1,2-benzoquinones; benzoquinone | |
| 4-cumylphenol [no description available] | 2.15 | 1 | 0 | diarylmethane | |
| 5-methylisatin 5-methylisatin: structure in first source | 2.15 | 1 | 0 | ||
| 2-hydrazinobenzothiazole [no description available] | 2.15 | 1 | 0 | ||
| acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine. | 1.97 | 1 | 0 | acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid | antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary |
| 1,2,3-trimethoxybenzene 1,2,3-trimethoxybenzene : A methoxybenzene that is benzene substituted by methoxy groups at positions 1, 2 and 3 respectively. | 2.15 | 1 | 0 | methoxybenzenes | plant metabolite |
| 2-amino-5-chlorobenzophenone 2-amino-5-chlorbenzophenone: structure given in first source | 2.15 | 1 | 0 | ||
| 1H-indazol-3-amine 1H-indazol-3-amine: structure in first source | 2.11 | 1 | 0 | indazoles | |
| diphenamid diphenamid: do not confuse with anti-inflammatory agent difenpiramide; structure | 2.15 | 1 | 0 | diarylmethane | |
| 4-(4-nitrobenzyl)pyridine [no description available] | 2.15 | 1 | 0 | ||
| 1,1'-methylenedi-2-naphthol 1,1'-methylenedi-2-naphthol: piscicide | 2.11 | 1 | 0 | ||
| 5-methyl-3-phenylisoxazole-4-carboxylic acid 5-methyl-3-phenylisoxazole-4-carboxylic acid: has anti-tumor, antiviral, hypoglycemic, antifungal and anti-HIV activities; structure in first source | 2.15 | 1 | 0 | ||
| tricarballylic acid tricarballylic acid: RN given refers to parent cpd. tricarballylic acid : A tricarboxylic acid that is glutaric acid in which one of the beta-hydrogens is substituted by a carboxy group. | 2.11 | 1 | 0 | tricarboxylic acid | |
| 2-acetylbenzofuran 2-acetylbenzofuran: structure in first source | 2.15 | 1 | 0 | ||
| pyrazon pyrazon: structure; do not confuse with phenazone which is a synonym to antipyrine. chloridazon : A pyridazinone that is pyridazin-3(2H)-one substituted by an amino group at position 5, a chloro group at position 4 and a phenyl group at position 2. | 2.15 | 1 | 0 | benzenes; organochlorine compound; primary amino compound; pyridazinone | environmental contaminant; herbicide; xenobiotic |
| 2-amino-5-nitrobenzophenone 2-amino-5-nitrobenzophenone: urinary metabolite of nitrazepam | 2.15 | 1 | 0 | ||
| (4-tert-Butyl-phenoxy)-acetic acid [no description available] | 2.15 | 1 | 0 | monocarboxylic acid | |
| popop [no description available] | 2.11 | 1 | 0 | 1,3-oxazoles | fluorochrome |
| 2-tert-butylhydroquinone 2-tert-butylhydroquinone: an anticarcinogenic and chemopreventive agent. 2-tert-butylhydroquinone : A member of the class of hydroquinones in which one of the ring hydrogens of hydroquinone is replaced by a tert-butyl group. | 2.11 | 1 | 0 | hydroquinones | food antioxidant |
| 7-hydroxychlorpromazine 7-hydroxychlorpromazine: RN given refers to parent cpd | 2.11 | 1 | 0 | phenothiazines | |
| lenacil lenacil: Russian drug. herbicide : A substance used to destroy plant pests.. lenacil : A cyclopentapyrimidine that is 6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione substituted by a cyclohexyl group at position 3. | 2.15 | 1 | 0 | cyclopentapyrimidine | agrochemical; environmental contaminant; herbicide; xenobiotic |
| cme-carbodiimide [no description available] | 2.11 | 1 | 0 | ||
| chlordesmethyldiazepam [no description available] | 2.15 | 1 | 0 | benzodiazepine | |
| 2-amino-2',5-dichlorobenzophenone 2-amino-2',5-dichlorobenzophenone: structure given in first source | 2.15 | 1 | 0 | ||
| 2-(2'-hydroxyphenyl)benzimidazole 2-(2'-hydroxyphenyl)benzimidazole: structure in first source | 2.15 | 1 | 0 | ||
| 4-phthalimidobutyric acid 4-phthalimidobutyric acid: teratogen; RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| azabutyrone azabutyrone: Russian drug; RN given refers to parent cpd; structure | 2.15 | 1 | 0 | ||
| 2-(2-hydroxyphenyl)benzothiazole 2-(1,3-benzothiazol-2-yl)phenol : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a 2-hydroxyphenyl group at position 2. | 2.15 | 1 | 0 | benzothiazoles; phenols | geroprotector |
| 4,5-dichlorocatechol [no description available] | 2.15 | 1 | 0 | ||
| cyclacillin Cyclacillin: A cyclohexylamido analog of PENICILLANIC ACID. | 2.11 | 1 | 0 | penicillin | antibacterial drug |
| n-butylbenzenesulfonamide N-butylbenzenesulfonamide: a neurotoxic plasticising agent. N-butylbenzenesulfonamide : A sulfonamide that is benzenesulfonamide substituted by a butyl group at the nitrogen atom. It has been isolated from the plant Prunus africana and has been shown to exhibit antiandrogenic activity. | 2.15 | 1 | 0 | sulfonamide | neurotoxin; plant metabolite |
| 3-phenoxybenzoic acid 3-phenoxybenzoic acid: metabolite associated with exposure to pyrethroid insecticides. 3-phenoxybenzoic acid : A phenoxybenzoic acid in which the phenoxy group is meta to the carboxy group. It is a metabolite of pyrethroid insecticides. | 2.15 | 1 | 0 | phenoxybenzoic acid | human xenobiotic metabolite; marine xenobiotic metabolite |
| strombine N-methyliminodiacetic acid: structure in first source | 2.11 | 1 | 0 | ||
| 2-(2-hydroxyethylmercapto)benzothiazole 2-(2-hydroxyethylmercapto)benzothiazole: reaction product of 2-mercaptobenzothiazole, well-known rubber vulcanization accelerator; structure in first source | 2.15 | 1 | 0 | ||
| carboxin Carboxin: A systemic agricultural fungicide and seed treatment agent.. carboxin : An anilide obtained by formal condensation of the amino group of aniline with the carboxy group of 2-methyl-5,6-dihydro-1,4-oxathiine-3-carboxylic acid. A fungicide for control of bunts and smuts that is normally used as a seed treatment. | 2.15 | 1 | 0 | anilide fungicide; anilide; enamide; organosulfur heterocyclic compound; oxacycle; secondary carboxamide | antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor |
| meturin [no description available] | 2.15 | 1 | 0 | ||
| platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae. | 2.1 | 1 | 0 | elemental platinum; nickel group element atom; platinum group metal atom | |
| aluminum chloride Aluminum Chloride: A compound with the chemical formula AlCl3; the anhydrous salt is used as a catalyst in organic chemical synthesis, and hydrated salts are used topically as antiperspirants, and for the management of HYPERHYDROSIS. | 2.17 | 1 | 0 | aluminium coordination entity | Lewis acid |
| 2-bromo-N-phenylbenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-chlorohippuric acid 4-chlorohippuric acid: metabolite of zomepirac; RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 4-chlorophenoxyacetic acid 4-chlorophenoxyacetic acid: RN given refers to parent cpd; structure. (4-chlorophenoxy)acetic acid : A chlorophenoxyacetic acid that is phenoxyacetic acid carrying a chloro substituent at position 4. | 2.15 | 1 | 0 | chlorophenoxyacetic acid; monochlorobenzenes | phenoxy herbicide |
| 2,5-dichloro-1,4-phenylenediamine 2,5-dichloro-1,4-phenylenediamine: structure in first source | 2.15 | 1 | 0 | ||
| metribuzin metribuzin : A member of the class of 1,2,4-triazines that is 1,2,4-triazin-5(4H)-one substituted by an amino group at position 4, tert-butyl group at position 6 and a methylsulfanyl group at position 3. | 2.15 | 1 | 0 | 1,2,4-triazines; cyclic ketone; organic sulfide | agrochemical; environmental contaminant; herbicide; xenobiotic |
| thymolphthalein Thymolphthalein: Used as a pH indicator and as a reagent for blood after decolorizing the alkaline solution by boiling with zinc dust. | 2.11 | 1 | 0 | terpene lactone | |
| n-chlorosuccinimide N-chlorosuccinimide : A five-membered cyclic dicarboximide compound having a chloro substituent on the nitrogen atom. | 1.95 | 1 | 0 | dicarboximide; pyrrolidinone | |
| 1,4,5,8-naphthalenetetracarboxylic acid 1,4,5,8-naphthalenetetracarboxylic acid: structure given in first source | 2.11 | 1 | 0 | ||
| (7S,9S)-7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione [no description available] | 2.11 | 1 | 0 | anthracycline | |
| 2,5-dimethyl-3-furancarboxanilide 2,5-dimethyl-3-furancarboxanilide: structure | 2.15 | 1 | 0 | ||
| hydroxyphenylazouracil Hydroxyphenylazouracil: Inhibitor of DNA replication in gram-positive bacteria. | 2.11 | 1 | 0 | ||
| canadine canadine: RN given refers to cpd without isomeric designation; structure. canadine : A berberine alkaloid that is 5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline substituted by methoxy groups at positions 9 and 10. | 2.11 | 1 | 0 | aromatic ether; berberine alkaloid; organic heteropentacyclic compound; oxacycle | |
| moricizine hydrochloride moricizine hydrochloride : A hydrochloride salt obtained from equimola amounts of moricizine and hydrogen chloride. | 2.15 | 1 | 0 | hydrochloride | anti-arrhythmia drug |
| 2-benzimidazolylguanidine 2-benzimidazolylguanidine: effects chloride efflux in tissue; RN given refers to parent cpd | 2.15 | 1 | 0 | aminoimidazole | |
| substance p [no description available] | 3.45 | 7 | 0 | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent |
| diflubenzuron Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group. | 2.15 | 1 | 0 | benzoylurea insecticide; monochlorobenzenes | insect sterilant |
| pentafluorobenzoyl-n-phenylethylamine [no description available] | 2.15 | 1 | 0 | ||
| thidiazuron [no description available] | 2.15 | 1 | 0 | ureas | |
| phenthiazamine phenthiazamine: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 5,5-diphenylbarbituric acid 5,5-diphenylbarbituric acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 3-acetamidobenzoic acid N-acetyl-m-aminobenzoic acid: from Solanum laciniatum; structure in first source | 2.15 | 1 | 0 | ||
| pimonidazole pimonidazole: structure given in first source | 2.11 | 1 | 0 | ||
| dazoxiben hydrochloride [no description available] | 2.15 | 1 | 0 | ||
| flavone acetic acid flavone acetic acid: structure given in first source | 2.11 | 1 | 0 | ||
| succinylsulfanilamide [no description available] | 2.15 | 1 | 0 | ||
| adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit | 1.98 | 1 | 0 | adenosines; purines D-ribonucleoside | analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent |
| nitrogen trioxide [no description available] | 2.01 | 1 | 0 | nitrogen oxide | |
| benzylaminopurine benzylaminopurine: a plant growth regulator. N-benzyladenine : A member of the class of 6-aminopurines that is adenine in which one of the hydrogens of the amino group is replaced by a benzyl group. | 2.15 | 1 | 0 | 6-aminopurines | cytokinin; plant metabolite |
| trichlorophene trichlorophene: contains 20 carbon atoms; do not confuse with trichlorophene as name for trichloro derivs of 2,2'-methylenebisphenol (contain 13 carbon atoms) | 2.11 | 1 | 0 | ||
| verapamil hydrochloride verapamil hydrochloride : A racemate comprising equimolar amounts of dexverapamil hydrochloride and (S)-verapamil hydrochloride. | 2.11 | 1 | 0 | ||
| ciprofloxacin hydrochloride anhydrous [no description available] | 2.15 | 1 | 0 | hydrochloride | antibacterial drug; antiinfective agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor |
| src-820 r [no description available] | 2.15 | 1 | 0 | ||
| n(4)-acetylsulfadiazine N(4)-acetylsulfadiazine: main metabolite of sulfadiazine. N(4)-acetylsulfadiazine : A sulfonamide that is benzenesulfonamide substituted by an acetylamino group at position 4 and a pyrimidin-2-yl group at the nitrogen atom. It is a metabolite of the drug sulfadiazine. | 2.15 | 1 | 0 | acetamides; pyrimidines; sulfonamide | marine xenobiotic metabolite |
| 4-nitro-alpha-acetylamino-beta-hydroxypropiophenone 4-nitro-alpha-acetylamino-beta-hydroxypropiophenone: inhibitory agent for the differentiation of mammalian tuberculosis strains from other Mycobacteria | 2.15 | 1 | 0 | ||
| 4-aminomethylbenzoic acid [no description available] | 2.11 | 1 | 0 | benzoic acids | |
| cedrol cedrol: a cyclic terpenoid from cedarwood oil; 8-epicedrol is an epimer | 2.11 | 1 | 0 | cedrane sesquiterpenoid; tertiary alcohol | |
| formetamide formetamide: RN given refers to cpd with unspecified isomeric designation | 2.15 | 1 | 0 | ||
| isbufylline isbufylline: RN from Toxlit | 2.15 | 1 | 0 | ||
| propazole propazole: RN given refers to parent cpd; structure | 2.11 | 1 | 0 | benzimidazoles | |
| reserpic acid reserpic acid: inhibitor of norepinephrine transport into chromaffin vesicle ghosts; RN given refers to (3beta,16beta,17alpha,18beta,20alpha)-isomer parent cpd; structure given in first source | 2.11 | 1 | 0 | yohimban alkaloid | |
| pifexole pifexole: structure | 2.11 | 1 | 0 | ||
| n-phenylglycine N-phenylglycine: RN given refers to parent cpd. N-phenylglycine : A glycine carrying an N-phenyl substituent. | 7.13 | 1 | 0 | non-proteinogenic alpha-amino acid | allergen |
| Diphenolic acid diphenolic acid: an estrogenic ligand | 2.11 | 1 | 0 | bisphenol | |
| Melicopidine [no description available] | 2.11 | 1 | 0 | acridines | |
| phenylacetylglycine phenylacetylglycine : A N-acylglycine that is glycine substituted on nitrogen with a phenylacetyl group. | 2.15 | 1 | 0 | monocarboxylic acid amide; monocarboxylic acid; N-acylglycine | human metabolite; mouse metabolite |
| N-benzoylanthranilic acid N-benzoylanthranilic acid : An amidobenzoic acid comprising benzoic acid having a benzamido group at the 2-position. | 2.15 | 1 | 0 | amidobenzoic acid | |
| butinoline [no description available] | 2.15 | 1 | 0 | diarylmethane | |
| n-(2-carboxyphenyl)glycine [no description available] | 2.15 | 1 | 0 | ||
| resorufin [no description available] | 2.11 | 1 | 0 | phenoxazine | |
| n,n-dimethyl-4-anisidine [no description available] | 2.15 | 1 | 0 | ||
| n-benzoylpiperidine [no description available] | 2.15 | 1 | 0 | benzamides; N-acylpiperidine | |
| 2-phenylcyclopropanecarboxylic acid 2-phenylcyclopropanecarboxylic acid: RN given for (trans)-isomer; structure in first source | 2.15 | 1 | 0 | ||
| n-demethylantipyrine [no description available] | 2.15 | 1 | 0 | pyrazoles; ring assembly | |
| 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine [no description available] | 2.15 | 1 | 0 | 1,2,4-triazines | |
| 2-amino-5-bromopyridine [no description available] | 2.15 | 1 | 0 | ||
| n-benzoylalanine, (dl-ala)-isomer [no description available] | 2.15 | 1 | 0 | alanine derivative; N-acyl-amino acid | metabolite |
| bicinchoninic acid [no description available] | 2.15 | 1 | 0 | ||
| vinburnine [no description available] | 2.11 | 1 | 0 | alkaloid | |
| betamipron [no description available] | 2.15 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| pacein PAcein: structure. pacein : A member of the class of benzofurans that is dibenzo[b,d]furan-3,7-dione bearing two methyl substituents at positions 1 and 9 as well as two 2,4-dihydroxy-6-methylanilino substituents at positions 2 and 8.. orcein : A variable mixture of several compounds isolated from lichens, the eight most abundant being alpha-aminoorcein, alpha-hydroxyorcein, beta-aminoorcein, gamma-aminoorcein, beta-hydroxyorcein, gamma-hydroxyorcein, beta-aminoorceimine and beta-aminoorceimine (all are phenoxazine-based). It is used for the demonstration of elastic fibres as well as to stain the rough endoplasmic reticulum of hepatitis B infected liver cells. | 2.11 | 1 | 0 | ||
| alantolactone alantolactone: allergenic sesquiterpene lactone; crystalline mixture of alantolactones from group of sesquiterpenes; structure. alantolactone : A sesquiterpene lactone that is 3a,5,6,7,8,8a,9,9a-octahydronaphtho[2,3-b]furan-2-one bearing two methyl substituents at positions 5 and 8a as well as a methylidene substituent at position 3. | 2.11 | 1 | 0 | naphthofuran; olefinic compound; sesquiterpene lactone | antineoplastic agent; apoptosis inducer; plant metabolite |
| 2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide 2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide: structure | 2.11 | 1 | 0 | ||
| benzoylpropionic acid benzoylpropionic acid: structure in first source. 4-oxo-4-phenylbutyric acid : A 4-oxo monocarboxylic acid that is butyric acid bearing oxo and phenyl substituents at position 4. | 2.15 | 1 | 0 | 4-oxo monocarboxylic acid | hapten |
| tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity | 2.11 | 1 | 0 | bisbenzylisoquinoline alkaloid; isoquinolines | |
| Evoxine [no description available] | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid: precursor of mutagenic nitroso cpd in soy sauce; structure given in first source | 2.15 | 1 | 0 | harmala alkaloid | |
| stictic acid stictic acid: antioxidant from lichen, Usnea articulata; structure in first source | 2.11 | 1 | 0 | aromatic ether | |
| tetracyanoquinodimethane tetracyanoquinodimethane: structure. tetracyanoquinodimethane : A quinodimethane that is p-quinodimethane in which the methylidene hydrogens are replaced by cyano groups. | 1.98 | 1 | 0 | alicyclic compound; nitrile; quinodimethane | |
| gallocyanine gallocyanine: structure; gallocyanine-chrome alum is used as a nuclear stain to quantitate nucleic acids. gallocyanin : An organic chloride salt composed of 1-carboxy-7-(dimethylamino)-3,4-dihydroxyphenoxazin-5-ium and chloride ions in a 1:1 ratio. A histological dye used in solution with an iron alum mordant as a hematoxylin substitute in the H&E stain. | 2.11 | 1 | 0 | ||
| N-Benzylphthalimide [no description available] | 2.15 | 1 | 0 | isoindoles | |
| n-acetylhistidine N-acetylhistidine: RN given refers to (L)-isomer. N-acetylhistidine : A histidine derivative that is histidine in which one of the hydrogens of the alpha-amino group is substituted by an acetyl group.. N-acetyl-L-histidine : A histidine derivative that is L-histidine having an acetyl substituent on the alpha-nitrogen. | 2.67 | 3 | 0 | L-histidine derivative; N-acetyl-L-amino acid; N-acetylhistidine | animal metabolite |
| pyromellitic diimide pyromellitic diimide: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 4'-bromosalicylanilide 4'-bromosalicylanilide: photoproduct from UV-irradiation of tribromsalan; structure | 2.15 | 1 | 0 | ||
| 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane: methoxychlor metabolite | 2.15 | 1 | 0 | bisphenol | |
| terephthalamide [no description available] | 2.15 | 1 | 0 | benzenedicarboxamide | |
| 3(2h)-pyridazinone, 4-chloro-5-(dimethylamino)-2-phenyl- [no description available] | 2.15 | 1 | 0 | ||
| 2-nitrophenylacetic acid (2-nitrophenyl)acetic acid : A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the ortho- position by a nitro group. | 2.15 | 1 | 0 | C-nitro compound; phenylacetic acids | |
| onychine [no description available] | 2.15 | 1 | 0 | ||
| 4'-methoxyflavone 4'-methoxyflavone: from seeds of Psoralea corylifolia (Fabaceae); structure in first source | 2.15 | 1 | 0 | ether; flavonoids | |
| 1,3-diphenyl-2-aminopropane 1,3-diphenyl-2-aminopropane: structure given in the first source | 2.15 | 1 | 0 | ||
| propylsulfonic acid propylsulfonic acid: RN given refers to cpd without locant for propyl moiety | 2.11 | 1 | 0 | ||
| 2,2-diphenylpropionic acid 2,2-diphenylpropionic acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| 3,4-dimethoxyphenylacetamide 3,4-dimethoxyphenylacetamide: structure | 2.15 | 1 | 0 | ||
| 2-amino-5-bromobenzoic acid 2-amino-5-bromobenzoic acid: structure in first source | 2.15 | 1 | 0 | ||
| 2-(1H-benzimidazol-2-yl)aniline 2-(1H-benzimidazol-2-yl)aniline : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a 2-aminophenyl group at position 2. | 2.15 | 1 | 0 | benzimidazoles; primary arylamine; substituted aniline | geroprotector |
| N-Acetylhomoveratrylamine [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-chlorobenzenesulfonamide [no description available] | 2.15 | 1 | 0 | ||
| 4-nitrophenyl dimethylcarbamate [no description available] | 2.15 | 1 | 0 | ||
| 8-(4-tolylsulfonylamino)quinoline 8-(4-tolylsulfonylamino)quinoline: has diabetogenic properties; can be used for fluorometric determination of zinc; structure given in first source | 2.15 | 1 | 0 | sulfonamide | |
| 5-methoxyindole-3-carbaldehyde [no description available] | 2.15 | 1 | 0 | indoles | |
| 1-cyclohexyl-3-(2-(4-morpholinyl)ethyl)carbodiimide N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide : A carbodiimide having cyclcohexyl and 2-(4-morpholinyl)ethyl as the two N-substituents. | 2.11 | 1 | 0 | carbodiimide; morpholines | cross-linking reagent |
| 6,6'-dithiodinicotinic acid 6,6'-dithiodinicotinic acid: RN given refers to parent cpd; structure | 2.11 | 1 | 0 | ||
| 2-oxo-1,2-dihydroquinoline-4-carboxylic acid [no description available] | 2.15 | 1 | 0 | quinolinemonocarboxylic acid | |
| 6-methoxy-2,3,4,9-tetrahydropyrido[3,4-b]indol-1-one [no description available] | 2.15 | 1 | 0 | beta-carbolines | |
| pd 147953 [no description available] | 2.15 | 1 | 0 | ||
| fenozan fenozan: do not confuse with the phenothiazine phenosan | 2.15 | 1 | 0 | ||
| va 061 VA 061: a water-soluble radical initiator; structure in first source | 2.11 | 1 | 0 | ||
| n-acetyltyrosine, (dl)-isomer N-acetyltyrosine: RN given refers to (L)-isomer. N-acetyltyrosine : An N-acetyl-amino acid that is tyrosine with an amine hydrogen substituted by an acetyl group. | 3.28 | 6 | 0 | N-acetyl-amino acid; phenols; tyrosine derivative | human urinary metabolite |
| 5-phenylbarbituric acid 5-phenylbarbituric acid: RN given refers to parent cpd | 2.15 | 1 | 0 | ||
| cinchonine [no description available] | 2.11 | 1 | 0 | (8xi)-cinchonan-9-ol; cinchona alkaloid | metabolite |
| diethylpropion hydrochloride diethylpropion hydrochloride : The hydrochloride salt of diethylpropion. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as an anoretic in the short term management of obesity. | 2.15 | 1 | 0 | hydrochloride | appetite depressant |
| 5-bromouridine 5-bromouridine : A uridine having a bromo substituent at the 5-position. | 2 | 1 | 0 | uridines | mutagen |
| n(6)-(delta(2)-isopentenyl)adenine N(6)-dimethylallyladenine : A 6-isopentenylaminopurine in which has the isopentenyl double bond is located between the 2 and 3 positions of the isopentenyl group. | 2.11 | 1 | 0 | 6-isopentenylaminopurine | cytokinin |
| glycyltryptophan glycyltryptophan: RN given refers to (L)-isomer. Gly-Trp : A dipeptide formed from glycine and L-tryptophan residues. | 1.96 | 1 | 0 | dipeptide | metabolite |
| 2-Phthalimidoglutaricacid [no description available] | 2.11 | 1 | 0 | glutamic acid derivative | |
| nsc-87877 NSC-87877: potent Shp2 (nonreceptor protein tyrosine phosphatase) inhibitor; structure in first source | 2.11 | 1 | 0 | ||
| 1-(4'-nitrophenyl)-2-aminopropane-1,3-diol 1-(4'-nitrophenyl)-2-aminopropane-1,3-diol: chloramphenicol minus dichloroacetamide side chain; RN given refers to cpd without isomeric designation | 2.15 | 1 | 0 | ||
| methyl lithocholate methyl lithocholate: RN given refers to (3alpha,5beta)-isomer | 2.11 | 1 | 0 | ||
| nipecotic acid amide nipecotic acid amide: RN & N1 form 9th CI Form Index; RN given refers to cpd without isomeric designation. nipecotamide : The amide resulting from the formal condensation of nipecotic acid with ammonia. | 2.11 | 1 | 0 | piperidinecarboxamide | |
| beta-hydroxyphenylalanine beta-hydroxyphenylalanine: RN given refers to beta cpd | 2.15 | 1 | 0 | ||
| n-acetyltryptophanamide [no description available] | 2 | 1 | 0 | acetamides; L-tryptophan derivative; primary carboxamide; secondary carboxamide | |
| pyrimidine dimers Pyrimidine Dimers: Dimers found in DNA chains damaged by ULTRAVIOLET RAYS. They consist of two adjacent PYRIMIDINE NUCLEOTIDES, usually THYMINE nucleotides, in which the pyrimidine residues are covalently joined by a cyclobutane ring. These dimers block DNA REPLICATION. | 1.98 | 1 | 0 | ||
| dimethacrine dimethacrine: minor descriptor (75-84); on-line & Index Medicus search ACRIDINES (75-84); RN given refers to parent cpd without isomeric designation | 2.11 | 1 | 0 | acridines | |
| dehydroabietic acid dehydroabietic acid: major aquatic toxicant in effluent of pulp and paper mills. dehydroabietic acid : An abietane diterpenoid that is abieta-8,11,13-triene substituted at position 18 by a carboxy group.. dehydroabietate : A monocarboxylic acid anion that is the conjugate base of dehydroabietic acid, obtained by deprotonation of the carboxy group. | 2.11 | 1 | 0 | abietane diterpenoid; carbotricyclic compound; monocarboxylic acid | allergen; metabolite |
| 3-(n-salicyloyl)amino-1,2,4-triazole 3-(N-salicyloyl)amino-1,2,4-triazole: synthetic chelating agent used chiefly to inhibit corrosion of copper | 2.15 | 1 | 0 | ||
| 7-chloro-4-aminoquinoline 7-chloro-4-aminoquinoline: structure given in first source | 2.15 | 1 | 0 | aminoquinoline | |
| acridine-9-carboxylic acid [no description available] | 2.15 | 1 | 0 | ||
| 1-phenazinecarboxylic acid 1-phenazinecarboxylic acid: from Streptomyces cinnamonensis; RN given refers to parent cpd; structure given in first source. phenazine-1-carboxylic acid : An aromatic carboxylic acid that is phenazine substituted at C-1 with a carboxy group. | 2.15 | 1 | 0 | aromatic carboxylic acid; monocarboxylic acid; phenazines | antifungal agent; antimicrobial agent; bacterial metabolite |
| 4,5-diphenyl-1,5-dihydroimidazol-2-one [no description available] | 2.15 | 1 | 0 | stilbenoid | |
| 2-hydroxy-1,2-bis(methoxyphenyl)ethanone 2-hydroxy-1,2-bis(methoxyphenyl)ethanone: structure given in first source | 2.15 | 1 | 0 | ||
| 4-deoxypyridoxine 5'-phosphate [no description available] | 2.11 | 1 | 0 | ||
| 4-methyl-N-(phenylmethyl)benzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-n-butylaminobenzoic acid 4-n-butylaminobenzoic acid: degradation product of tetracaine. 4-(butylamino)benzoic acid : 4-Aminobenzoic acid in which one of the hydrogens attached to the nitrogen is substituted by a butyl group. | 2.15 | 1 | 0 | aromatic amino acid | |
| fluoren-9-ol [no description available] | 2.15 | 1 | 0 | ||
| 1-(2-carboxyethyl)uracil [no description available] | 2.15 | 1 | 0 | ||
| 1-benzylindole 1-benzylindole: structure | 2.15 | 1 | 0 | ||
| 2,3-bis(2-pyridinyl)quinoxaline [no description available] | 2.15 | 1 | 0 | quinoxaline derivative | |
| 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol : A member of the class of hydroxybiphenyls formed formally by chlorination of biphenyl-4,4'-diol at C-3, -3', -5 and -5'. | 2.15 | 1 | 0 | dichlorobenzene; hydroxybiphenyls | |
| 5-nitro-2-(1-piperidinyl)pyridine [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 4-(phenylthio)butanoic acid 4-(phenylthio)butanoic acid: structure in first source | 2.11 | 1 | 0 | ||
| 2-amino-5,7-dimethyl-1,8-naphthyridine 2-amino-5,7-dimethyl-1,8-naphthyridine: structure in first source | 2.15 | 1 | 0 | ||
| bis-a-tda bis-A-TDA: structure given in first source | 2.11 | 1 | 0 | ||
| 1-amino-2-phenylethylphosphonic acid 1-amino-2-phenylethylphosphonic acid: RN given refers to cpd without isomeric designation: structure given in first source | 2.11 | 1 | 0 | ||
| 5-benzyloxytryptophan [no description available] | 2.15 | 1 | 0 | ||
| 4-fluoro-alpha-hydroxybenzeneacetic acid 4-fluoro-alpha-hydroxybenzeneacetic acid: an aprepitant urinary metabolite; structure in first source | 2.11 | 1 | 0 | ||
| Isopteropodin [no description available] | 2.11 | 1 | 0 | indolizines | |
| benzpiperylone benzpiperylone: spelled benzopiperylone in title | 2.11 | 1 | 0 | pyrazoles; ring assembly | |
| 2,5-diethoxy-4-morpholinoaniline 2,5-diethoxy-4-morpholinoaniline: structure in first source | 2.15 | 1 | 0 | ||
| 3-hydroxy-3-phenacyloxindole [no description available] | 2.15 | 1 | 0 | ||
| carbobenzoxyphenylalanine, (dl-phe)-isomer [no description available] | 2.15 | 1 | 0 | ||
| s-nitrosoglutathione [no description available] | 2.05 | 1 | 0 | glutathione derivative; nitrosothio compound | bronchodilator agent; nitric oxide donor; platelet aggregation inhibitor; signalling molecule |
| gamma-fagarine gamma-fagarine: active alkaloid of Chinese medicines from Dictamni radicis cortex (Rutaceae); structure given in first source | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| carboxyamido-triazole carboxyamido-triazole: structure given in first source; coccidiostat; U.S. patent No. 4,590,201 | 2.11 | 1 | 0 | ||
| caprylates Caprylates: Derivatives of caprylic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain a carboxy terminated eight carbon aliphatic structure.. octanoate : A straight-chain saturated fatty acid anion that is the conjugate base of octanoic acid (caprylic acid); believed to block adipogenesis. | 5.33 | 13 | 1 | fatty acid anion 8:0; straight-chain saturated fatty acid anion | human metabolite; Saccharomyces cerevisiae metabolite |
| 3-carboxymethyl-6-benzyl-2,5-diketopiperazine 3-carboxymethyl-6-benzyl-2,5-diketopiperazine: formed in aqueous solution by aspartame; structure given in first source | 2.15 | 1 | 0 | organonitrogen compound; organooxygen compound | |
| 4-fluorobenzenesulfonamide 4-fluorobenzenesulfonamide: structure given in first source | 2.15 | 1 | 0 | ||
| tryptophan methyl ester tryptophan methyl ester: RN given refers to parent cpd(DL)-isomer | 1.96 | 1 | 0 | ||
| emoxypine succinate emoxypine succinate: has antihypoxic effects | 2.15 | 1 | 0 | ||
| n-acetylputrescine N-acetylputrescine : An N-monoacetylalkane-alpha,omega-diamine that is the N-monoacetyl derivative of putrescine. | 2.25 | 1 | 0 | N-monoacetylalkane-alpha,omega-diamine; N-substituted putrescine | metabolite; mouse metabolite |
| nsc 607097 [no description available] | 2.11 | 1 | 0 | ||
| n-carbamyltryptophan N-carbamyltryptophan: RN given refers to (D)-isomer | 2.15 | 1 | 0 | ||
| pacifenol pacifenol: isolated from sea weeds and marine alga Laurencia claviformis; RN refers to (2R,5R,5aR,7S,8S,9aS)-isomer; structure in first source | 2.11 | 1 | 0 | ||
| 2,4,6-trimethoxyacetophenone 2,4,6-trimethoxyacetophenone: structure in first source | 2.15 | 1 | 0 | ||
| peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES). | 2.43 | 2 | 0 | nitrogen oxoacid | |
| 1-(2-hydroxyethyl)-3,5-diphenyl-1h-pyrazole 1-(2-hydroxyethyl)-3,5-diphenyl-1H-pyrazole: structure given in first source | 2.15 | 1 | 0 | ||
| 4-methyoxybenzoyl-n-glycine [no description available] | 2.15 | 1 | 0 | N-acylglycine | |
| 5-ethoxy-2-ethylmercaptobenzimidazole 5-ethoxy-2-ethylmercaptobenzimidazole: has activating effect on peritoneal macrophages; RN given does not give position for ethoxy group | 2.15 | 1 | 0 | ||
| 5(6)-1(2h)-phthalazinonyl-4(1h)-benzimidazole-2-carbamate methyl ester [no description available] | 2.15 | 1 | 0 | ||
| 3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist | 2.1 | 1 | 0 | ||
| l 733060 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source | 2.07 | 1 | 0 | piperidines | |
| n-phenyliminodiacetic acid [no description available] | 2.53 | 2 | 0 | ||
| teomorfolin teomorfolin: structure given in first source | 2.15 | 1 | 0 | ||
| 1-(1,3-benzodioxol-5-yl)-3-(1-piperidinyl)-1-propanone [no description available] | 2.15 | 1 | 0 | benzodioxoles | |
| n-(aminocarbonyl)-2-chlorobenzenesulfonamide [no description available] | 2.15 | 1 | 0 | ||
| 3-hydroxy-2-quinoxalinepropionic acid [no description available] | 2.15 | 1 | 0 | ||
| 8-(methylsulfonylamino)quinoline 8-(methylsulfonylamino)quinoline: has diabetogenic properties; structure given in first source | 2.15 | 1 | 0 | ||
| naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes. | 3.44 | 1 | 1 | methoxynaphthalene; monocarboxylic acid | antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic |
| singlet oxygen Singlet Oxygen: An excited state of molecular oxygen generated photochemically or chemically. Singlet oxygen reacts with a variety of biological molecules such as NUCLEIC ACIDS; PROTEINS; and LIPIDS; causing oxidative damages. | 2.15 | 1 | 0 | chalcogen; monoatomic oxygen; nonmetal atom | macronutrient |
| cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors. | 2.11 | 1 | 0 | 2,6-diaminopurines | antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor |
| n(4)-acetylsulfamonomethoxine N(4)-acetylsulfamonomethoxine: main urinary metabolite of sulfamonomethoxine in pigs | 2.15 | 1 | 0 | ||
| 8-(4-benzenesulfonylamino)quinoline 8-(4-benzenesulfonylamino)quinoline: has diabetogenic properties; structure given in first source | 2.15 | 1 | 0 | ||
| methindione methindione: used in treatment of epilepsy; RN given refers to parent cpd; structure | 2.15 | 1 | 0 | ||
| 3,4-dihydroxybenzophenone 3,4-dihydroxybenzophenone: structure in first source | 2.15 | 1 | 0 | ||
| cystamine hydrochloride [no description available] | 2.11 | 1 | 0 | ||
| gamma-propanol [no description available] | 2.15 | 1 | 0 | ||
| dipiperidinoethane-di-n-oxide dipiperidinoethane-di-N-oxide: oxidized neurotoxic dipiperidinoethane deriv; structure given in first source | 2.11 | 1 | 0 | ||
| 2-[(3-oxo-1-cyclohexenyl)amino]benzonitrile [no description available] | 2.15 | 1 | 0 | benzenes; nitrile | |
| isonicotinylamide gaba [no description available] | 2.15 | 1 | 0 | ||
| 5-fluorotryptamine monohydrochloride [no description available] | 2.15 | 1 | 0 | ||
| 4-iodo-n-(2-(4-morpholinyl)ethyl)benzamide 4-iodo-N-(2-(4-morpholinyl)ethyl)benzamide: the iodinated analog of moclobemide; structure given in first source | 2.15 | 1 | 0 | ||
| 3-(hydroxyacetyl)indole 3-(hydroxyacetyl)indole: structure in first source | 2.15 | 1 | 0 | indoles | |
| n-(4-aminophenylsulfonyl)morpholine compound 82 208: structure given in first source | 2.15 | 1 | 0 | ||
| 1H-indol-3-yl-(4-methoxyphenyl)methanone [no description available] | 2.15 | 1 | 0 | N-acylindole | |
| 2-amino-5-phenyl-1,3,4-thiadiazole 2-amino-5-phenyl-1,3,4-thiadiazole: structure in first source | 2.15 | 1 | 0 | ||
| benzyl-beta-d-xyloside benzyl-beta-D-xyloside: RN given refers to (beta-D)-isomer | 2.11 | 1 | 0 | ||
| 2,2'-(3-methylcyclohexane-1,1-diyl)diacetic acid [no description available] | 2.11 | 1 | 0 | dicarboxylic acid | |
| 2,4-dinitrophenylacetic acid 2,4-dinitrophenylacetic acid: RN given refers to parent cpd | 2.11 | 1 | 0 | ||
| N-(1-phenylethyl)acetamide N-(1-phenylethyl)acetamide : A member of the class of acetamides resulting from the formal condensation of the amino group of 1-phenylethylamine with 1 mol eq. of acetic acid. | 2.15 | 1 | 0 | acetamides; secondary carboxamide | |
| sitosterol, (3beta)-isomer Sobatum: tradename; active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity. sitosterol : A member of the class of phytosterols that is stigmast-5-ene substituted by a beta-hydroxy group at position 3. | 2.11 | 1 | 0 | 3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; C29-steroid; phytosterols; stigmastane sterol | anticholesteremic drug; antioxidant; mouse metabolite; plant metabolite; sterol methyltransferase inhibitor |
| (5-Phenyl-1,2,4-triazol-3-yl)urea [no description available] | 2.11 | 1 | 0 | benzenes | |
| fumagillol fumagillol: from Penicillium jensenii; FR 65814 is an analog; structure given in first source. fumagillol : A sesquiterpenoid with antimicrobial properties. | 2.11 | 1 | 0 | secondary alcohol; sesquiterpenoid; spiro-epoxide | antimicrobial agent |
| vacquinol-1 [no description available] | 2.11 | 1 | 0 | ||
| alpha-(trichloromethyl)-4-pyridineethanol alpha-(trichloromethyl)-4-pyridineethanol: activates caspase-3 | 2.15 | 1 | 0 | pyridines | |
| aspidospermine aspidospermine: an indole fused to a qunoline; isolated from Aspidosperma tree; structure given in first source. aspidospermine : An indole alkaloid having the structure of aspirospermidine methoxylated at C-17 and acetylated at N-1. | 2.11 | 1 | 0 | indole alkaloid | |
| guaiol guaiol: structure in first source | 2.11 | 1 | 0 | guaiane sesquiterpenoid | |
| ml 204 ML 204: modulates both TRPC4 and TRPC5 channels; structure in first source | 2.15 | 1 | 0 | ||
| eudesmin eudesmin: RN refers to (1R-(1alpha,3aalpha,4alpha,6aalpha))-isomer; structure given in first source; very similar to pinoresinol | 2.15 | 1 | 0 | ||
| benzatropine methanesulfonate [no description available] | 2.11 | 1 | 0 | ||
| 2-amino-4-methyl-3-nitropyridine [no description available] | 2.15 | 1 | 0 | ||
| pseudoyohimbine [no description available] | 2.11 | 1 | 0 | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | |
| gant58 GANT58: inhibits hedgehog signalling; structure in first source | 2.11 | 1 | 0 | pyridines | |
| 4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline 4,4-bis(hydroxymethyl)-2-phenyl-2-oxazoline: Anticonvulsant | 2.15 | 1 | 0 | ||
| nsc 88915 4-pregnen-21-ol-3,20-dione-21-(4-bromobenzenesufonate): a tyrosyl-DNA phosphodiesterase inhibitor; structure in first source | 2.11 | 1 | 0 | ||
| o-acetylsolasodine [no description available] | 2.11 | 1 | 0 | ||
| viroallosecurinine [no description available] | 2.11 | 1 | 0 | indolizines | |
| 4-methyl-2-quinazolinamine 4-methyl-2-quinazolinamine: from Streptomyces of TCM plant; structure in first source | 2.11 | 1 | 0 | ||
| 1-amino-9,10-dioxo-4-(3-sulfamoylanilino)anthracene-2-sulfonic acid 1-amino-9,10-dioxo-4-(3-sulfamoylanilino)anthracene-2-sulfonic acid: inhibits PH domain leucine-rich repeat protein phosphatase; structure in first source | 2.11 | 1 | 0 | ||
| adamantoylcytarabine adamantoylcytarabine: RN given refers to parent cpd; structure in Negwer, 5th ed, #4393 | 2.11 | 1 | 0 | ||
| n-acetylhistidine [no description available] | 2.15 | 1 | 0 | histidine derivative; N-acetyl-amino acid | |
| 6,11-dioxo-12-naphtho[2,3-b]indolizinecarboxylic acid ethyl ester [no description available] | 2.11 | 1 | 0 | naphthalenes | |
| noscapine Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.. (-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects. | 2.11 | 1 | 0 | aromatic ether; benzylisoquinoline alkaloid; cyclic acetal; isobenzofuranone; organic heterobicyclic compound; organic heterotricyclic compound; tertiary amino compound | antineoplastic agent; antitussive; apoptosis inducer; plant metabolite |
| LSM-1290 [no description available] | 2.11 | 1 | 0 | benzazepine alkaloid; cyclic acetal | |
| 1-(1-oxo-2-phenylethyl)-4-piperidinecarboxylic acid [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-glycineamide-5-chlorophenyl-2-pyrryl ketone [no description available] | 2.11 | 1 | 0 | ||
| nsc 154020 [no description available] | 2.11 | 1 | 0 | N-glycosyl compound | |
| 1-(4-chlorophenyl)-3-(2-ethoxyphenyl)urea [no description available] | 2.15 | 1 | 0 | ureas | |
| 4-methoxyxanthone 4-methoxyxanthone: a vasodilator; structure in first source | 2.15 | 1 | 0 | ||
| 4-[(1-naphthalenylamino)-oxomethyl]benzene-1,3-dicarboxylic acid [no description available] | 2.11 | 1 | 0 | 2-hydroxyisophthalic acid | |
| N-(4-nitrophenyl)-2-phenoxyacetamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 1-phenylindolin-2-one 1-phenylindolin-2-one: structure in first source | 2.15 | 1 | 0 | ||
| 1-(benzenesulfonyl)indole [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 2,4,4,6-Tetramethyl-1,4-dihydro-3,5-pyridinedicarbonitrile [no description available] | 2.15 | 1 | 0 | dihydropyridine | |
| 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one: structure in first source | 2.11 | 1 | 0 | cyclic ketone; quinuclidines | |
| pifithrin mu 2-phenylacetylenesulfonamide: induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia cells; also inhibits Hsp70 and autophagy | 2.15 | 1 | 0 | benzenes | |
| 5-(1,3-benzodioxol-5-yl)-N-(2,4-dimethylphenyl)-1,3,4-oxadiazol-2-amine [no description available] | 2.11 | 1 | 0 | benzodioxoles | |
| croton factor f1 croton factor F1: induces ornithine decarboxylase activity; structure given in first source. 16-hydroxyphorbol 13-decanoate 12-palmitate : A phorbol ester that consists of 16-hydroxyphorbol bearing O-hexadecanoyl (palmitoyl) and O-decanoyl substituents at position 12 and 13 respectively. | 2.11 | 1 | 0 | phorbol ester; tertiary alpha-hydroxy ketone | |
| medicarpin (-)-medicarpin : The (-)-enantiomer of medicarpin. | 2.11 | 1 | 0 | medicarpin | plant metabolite |
| 2-benzyloxybenzaldehyde [no description available] | 2.15 | 1 | 0 | ||
| 2-guanidine-4-methylquinazoline 2-guanidine-4-methylquinazoline: structure given in first source | 2.15 | 1 | 0 | ||
| N-phenylcarbamic acid 2-phenoxyethyl ester [no description available] | 2.15 | 1 | 0 | carbamate ester | |
| gitoxigenin gitoxigenin: structure | 2.11 | 1 | 0 | 14beta-hydroxy steroid; 16beta-hydroxy steroid; 3beta-hydroxy steroid | |
| aromoline aromoline: from roots of Stephania cepharantha; structure given in first source | 2.11 | 1 | 0 | ||
| 3,4-dihydro-2H-benzo[4,5]imidazo[2,1-b][1,3]thiazin-3-ol [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| nsc668394 [no description available] | 2.11 | 1 | 0 | ||
| mequindox Mequindox: a synthetic quinoxaline 1,4-dioxide derivative which can effectively improve growth and feed efficiency in animals; structure in first source | 2.15 | 1 | 0 | ||
| gant 61 GANT 61: a sonic hedgehog pathway inhibitor and Gli inhibitor; structure in first source. GANT61 : An aminal that is hexahydropyrimidine which is substituted on each nitrogen by a 2-(dimethylamino)benzyl group, and at the aminal carbon by a pyridin-4-yl group. A Hedgehog signaling pathway and Gli protein inhibitor. | 2.11 | 1 | 0 | aminal; dialkylarylamine; pyridines; substituted aniline; tertiary amino compound | antineoplastic agent; apoptosis inducer; glioma-associated oncogene inhibitor; Hedgehog signaling pathway inhibitor |
| N-[2-(dimethylamino)ethyl]-2,2-diphenylacetamide [no description available] | 2.15 | 1 | 0 | diarylmethane | |
| tryptophanamide tryptophanamide: used as inhibitor of chymotrypsin; RN given refers to cpd with unspecified isomeric designation. L-tryptophanamide : An amino acid amide that is the carboxamide of L-tryptophan. | 2 | 1 | 0 | amino acid amide; tryptophan derivative | human metabolite |
| nortriptyline hydrochloride [no description available] | 2.11 | 1 | 0 | organic tricyclic compound | geroprotector |
| ochratoxin a ochratoxin A: structure in first source & in Merck, 9th ed, #6549. ochratoxin A : A phenylalanine derivative resulting from the formal condensation of the amino group of L-phenylalanine with the carboxy group of (3R)-5-chloro-8-hydroxy-3-methyl-1-oxo-3,4-dihydro-1H-2-benzopyran-7-carboxylic acid (ochratoxin alpha). It is among the most widely occurring food-contaminating mycotoxins, produced by Aspergillus ochraceus, Aspergillus carbonarius and Penicillium verrucosum. | 2.25 | 1 | 0 | isochromanes; monocarboxylic acid amide; N-acyl-L-phenylalanine; organochlorine compound; phenylalanine derivative | Aspergillus metabolite; calcium channel blocker; carcinogenic agent; mycotoxin; nephrotoxin; Penicillium metabolite; teratogenic agent |
| Girgensonine [no description available] | 2.15 | 1 | 0 | nitrile | |
| Dubinidine [no description available] | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry. | 2.31 | 1 | 0 | octadec-9-enoic acid | antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent |
| formycin [no description available] | 2.01 | 1 | 0 | formycin | antineoplastic agent |
| n-acetylmethionine N-acetylmethionine: RN given refers to L-isomer. N-acetylmethionine : A methionine derivative that is methionine in which one of the amine hydrogens is substituted by an acetyl group. | 2.68 | 3 | 0 | L-methionine derivative; N-acetyl-L-amino acid; N-acetylmethionine | nutraceutical |
| N-[4-(methanesulfonamido)phenyl]acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-(2-oxazolo[4,5-b]pyridinyl)aniline [no description available] | 2.15 | 1 | 0 | 1,3-oxazoles | |
| 2-[(4-nitrophenyl)methylthio]-1,3-benzoxazole [no description available] | 2.15 | 1 | 0 | benzoxazole | |
| nsc 45641 [no description available] | 2.11 | 1 | 0 | ||
| 3-oxido-4,5-dihydro-[1,2,5]oxadiazolo[3,4-f]cinnolin-3-ium [no description available] | 2.15 | 1 | 0 | pyridazines | |
| 3-(2,4-difluoroanilino)-5,5-dimethyl-1-cyclohex-2-enone [no description available] | 2.15 | 1 | 0 | substituted aniline | |
| 1-phenyl-4-pyrazolol [no description available] | 2.15 | 1 | 0 | pyrazoles; ring assembly | |
| 3-(3,5-dimethyl-1-pyrazolyl)-1,2-benzothiazole 1,1-dioxide [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| 3-benzamido-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | benzofurans | |
| N-[2-(4-methoxyphenyl)ethyl]acetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 2-(1H-indol-3-ylthio)acetic acid [no description available] | 2.15 | 1 | 0 | indoles | |
| 3-bromo-N-[2-(4-nitroanilino)ethyl]benzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| 3-Methylbenzofuran-2-carboxylic acid [no description available] | 2.15 | 1 | 0 | benzofurans | |
| 5-(3,4-dimethoxyphenyl)-2H-tetrazole [no description available] | 2.15 | 1 | 0 | tetrazoles | |
| 1-(4-fluorophenyl)sulfonyl-4-(2-methoxyphenyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol [no description available] | 2.15 | 1 | 0 | alkylbenzene | |
| 2-phenylindole-3-carbaldehyde 2-phenylindole-3-carbaldehyde: structure in first source | 2.15 | 1 | 0 | ||
| 4-(2-pyridinylthio)benzofuro[3,2-d]pyrimidine [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 5-(4-nitrophenyl)-4-phenyl-2-thiazolamine [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 3-[6-(4-aminophenyl)-2-phenyl-4-pyrimidinyl]aniline [no description available] | 2.15 | 1 | 0 | pyrimidines | |
| geraniol [no description available] | 2.11 | 1 | 0 | 3,7-dimethylocta-2,6-dien-1-ol; monoterpenoid; primary alcohol | allergen; fragrance; plant metabolite; volatile oil component |
| 7-methoxyisoflavone 7-methoxyisoflavone : A methoxyisoflavone that is isoflavone substituted by a methoxy group at position 7. | 2.15 | 1 | 0 | 7-methoxyisoflavones | |
| aconitic acid cis-aconitic acid : The cis-isomer of aconitic acid. | 2.11 | 1 | 0 | aconitic acid | fundamental metabolite |
| LSM-32392 [no description available] | 2.15 | 1 | 0 | monoterpenoid | |
| N-[2-(1-cyclohexenyl)ethyl]-4-(4-morpholinylmethyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-(1-benzimidazolyl)-3-(1-cyclohex-3-enylmethoxy)-2-propanol [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-[2-(2-furanylmethylthio)ethyl]-4-methoxybenzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-acetamido-5-chloro-2-benzofurancarboxylic acid [no description available] | 2.15 | 1 | 0 | benzofurans | |
| [4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-(2,6-dimethoxyphenyl)methanone [no description available] | 2.15 | 1 | 0 | dimethoxybenzene | |
| 4-[4-methyl-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]morpholine [no description available] | 2.15 | 1 | 0 | N-arylpiperazine | |
| haplamine haplamine: isolated from Haplophyllum acutifolium; structure in first source | 2.15 | 1 | 0 | organic heterotricyclic compound; organonitrogen heterocyclic compound; oxacycle | |
| 5-(3,4-dimethoxyphenyl)-1H-1,2,4-triazol-3-amine [no description available] | 2.15 | 1 | 0 | triazoles | |
| 2-ethoxy-N-[4-(4-morpholinylsulfonyl)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-[(5-methyl-1H-1,2,4-triazol-3-yl)thio]-1-phenylethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| amygdalin [no description available] | 2.11 | 1 | 0 | ||
| 1-ethyl-6-methoxy-4-oxo-3-quinolinecarboxylic acid [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline : A member of the class of quinazolines that is quinazoline which is substituted at positions 2 and 4 by pyridin-4-yl and pyrrolidin-1-yl groups, respectively. | 2.15 | 1 | 0 | pyridines; pyrrolidines; quinazolines | |
| scp 1 [no description available] | 2.15 | 1 | 0 | ||
| N-(3-acetamidophenyl)-4-methoxybenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(3-acetamidophenyl)-3-chlorobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-methoxy-N-(5-methyl-3-isoxazolyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(2-fluorophenyl)-4-phenylmethoxybenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-[4-(diethylamino)phenyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| N-(2-furanylmethyl)-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | benzofurans | |
| 5-(2-phenylethyl)-1,3,4-thiadiazol-2-amine [no description available] | 2.15 | 1 | 0 | aromatic amine; thiadiazoles | |
| te 5 [no description available] | 2.15 | 1 | 0 | ||
| 2-[[anilino(oxo)methyl]amino]-4,5-dimethyl-3-thiophenecarboxamide [no description available] | 2.15 | 1 | 0 | ureas | |
| N-(4,6-dimethyl-2-pyrimidinyl)-1,3-benzothiazol-2-amine [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| 6-methylflavone 6-methylflavone: structure in first source | 2.15 | 1 | 0 | ||
| 2-methoxy-N-(2-pyridinyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-chloro-N-(2-phenylethyl)benzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| N1-(4H-1,2,4-triazol-4-yl)-4-nitrobenzamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| N-[2-(1-cyclohexenyl)ethyl]-4-fluorobenzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| tioxazafen tioxazafen : A 1,2,4-oxadizole in which the hydrogens at positions 3 and 5 have been replaced by phenyl and thiophen-2-yl groups, respectively. It is used as a broad spectrum nematicidal seed treatment. | 2.15 | 1 | 0 | 1,2,4-oxadiazole; thiophenes | agrochemical; nematicide |
| N-[5-(2-methylpropyl)-1,3,4-thiadiazol-2-yl]-2-thiophen-2-ylacetamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 1-(4-Methoxyphenyl)-2-nitroethylene 4-methoxy-beta-nitrostyrene: has vasodilator activity; structure in first source | 2.15 | 1 | 0 | methoxybenzenes | |
| alpha-phenylcinnamate alpha-phenylcinnamate: RN given refers to parent cpd | 2.11 | 1 | 0 | ||
| brd32048 BRD32048: inhibits ETV1 oncoprotein; structure in first source | 2.15 | 1 | 0 | methoxybenzenes; substituted aniline | |
| 2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 2-(3,4-dichlorophenyl)imidazo[1,2-a]pyrimidine [no description available] | 2.15 | 1 | 0 | imidazoles | |
| 5-(2-phenyl-4-triazolyl)-2H-tetrazole [no description available] | 2.15 | 1 | 0 | triazoles | |
| N-cyclohexyl-2,3-dihydroindole-1-carboxamide [no description available] | 2.15 | 1 | 0 | indolyl carboxylic acid | |
| 4-(benzylsulfanyl)thieno[2,3-d]pyrimidine 4-(benzylsulfanyl)thieno[2,3-d]pyrimidine : A thienopyrimidine that is thieno[2,3-d]pyrimidine which is substituted at position 4 by a benzylsulfanediyl group. | 2.15 | 1 | 0 | aryl sulfide; benzenes; thienopyrimidine | |
| 2-methyl-5-(5-methyl-2-furanyl)-3-(1-pyrrolyl)-4-thieno[2,3-d]pyrimidinone [no description available] | 2.15 | 1 | 0 | organic heterobicyclic compound; organonitrogen heterocyclic compound; organosulfur heterocyclic compound | |
| 1-[2-(dimethylamino)ethyl]-5-methoxy-N-methyl-2-indolecarboxamide [no description available] | 2.15 | 1 | 0 | indolecarboxamide | |
| N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-methoxybenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-(1H-benzimidazol-2-yl)quinoline [no description available] | 2.15 | 1 | 0 | quinolines | |
| 1-(4-Chlorophenyl)-2-[(1-methyl-1H-imidazol-2-yl)thio]ethan-1-one [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2,5-dimethylphenyl)-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| N-(4-methoxyphenyl)-2-benzofurancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 2-(9h-xanthen-9-yl)-malonic acid [no description available] | 2.15 | 1 | 0 | xanthenes | |
| 1-(1,3-benzothiazol-2-yl)-3-phenylurea [no description available] | 2.15 | 1 | 0 | ureas | |
| 1-hydroxy-2-phenyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one [no description available] | 2.15 | 1 | 0 | imidazoles | |
| N-(4-acetamidophenyl)-2-bromobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 4-bromo-N-phenacylbenzamide [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 1-(2,3-dihydroindol-1-yl)-2-(phenylthio)ethanone [no description available] | 2.15 | 1 | 0 | indoles | |
| N-[6-methyl-2-(4-methylphenyl)-5-benzotriazolyl]-3-pyridinecarboxamide [no description available] | 2.15 | 1 | 0 | triazoles | |
| N,N-dimethyl-N'-p-tolylsulfamide N,N-dimethyl-N'-p-tolylsulfamide : A member of the class of sulfamides that is N,N-dimethylsulfuric diamide substituted by a 4-methylphenyl group at the amino nitrogen atom. It is a metabolite of the agrochemical tolylfluanid. | 2.15 | 1 | 0 | sulfamides | marine xenobiotic metabolite |
| 2-(1-piperidinylmethyl)phenol 2-(1-piperidinylmethyl)phenol: structure in first source | 2.15 | 1 | 0 | ||
| 2,6-bis(benzimidazol-2-yl)pyridine 2,6-bis(benzimidazol-2-yl)pyridine: structure in first source | 2.15 | 1 | 0 | benzimidazoles | |
| 1-cyclohexyl-3-(2-phenylethyl)urea [no description available] | 2.15 | 1 | 0 | benzenes | |
| 1-(3,5-dichlorophenyl)-3-phenylurea [no description available] | 2.15 | 1 | 0 | ureas | |
| 1-(cyclohexylmethyl)-4-phenylpiperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-phenethyl-2-furamide [no description available] | 2.15 | 1 | 0 | aromatic amide; heteroarene | |
| paromomycin sulfate [no description available] | 2.15 | 1 | 0 | ||
| N,N,2-trimethyl-1-phenyl-5-benzimidazolesulfonamide [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-(phenylmethyl)-4-(3-pyridinyl)-2-thiazolamine [no description available] | 2.15 | 1 | 0 | aralkylamine | |
| N-(4-hydroxy-2-methyl-5-propan-2-ylphenyl)benzenesulfonamide [no description available] | 2.15 | 1 | 0 | monoterpenoid | |
| 2-amino-5-ethyl-4-(2-furanyl)-6-propyl-3-pyridinecarbonitrile [no description available] | 2.15 | 1 | 0 | nitrile; pyridines | |
| 2-ethoxy-N-[5-(methoxymethyl)-1,3,4-thiadiazol-2-yl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| vu0099704 VU0099704: an antagonist of protease activated receptor 4 (PAR-4); structure in first source | 2.15 | 1 | 0 | ||
| 3-(4-chlorophenyl)-2,5-dimethyl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available] | 2.15 | 1 | 0 | pyrazoles; ring assembly | |
| 1-(2-chloro-6-fluorophenyl)-[1,2,4]triazolo[4,3-a]quinoline [no description available] | 2.15 | 1 | 0 | triazoles | |
| 2-methyl-N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)propanamide [no description available] | 2.15 | 1 | 0 | pyrroloquinoline | |
| 2-methyl-5-[(2-methyl-4-quinolinyl)thio]-1,3,4-thiadiazole [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 5-methyl-1-(4-nitrophenyl)-2-oxo-2,5-dihydro-1h-pyrido(3,2-b)indole-3-carbonitrile VRX-413638: structure in first source | 2.15 | 1 | 0 | ||
| (3-hydroxy-5,6,7,8-tetrahydro-4H-cyclohepta[d]imidazol-2-yl)-phenylmethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 2-fluoro-N-phenacylbenzamide [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 4-(methoxymethyl)-6-methyl-2-(2-methylanilino)-3-pyridinecarbonitrile [no description available] | 2.15 | 1 | 0 | nitrile; pyridines | |
| 1-azepanyl-[2-methoxy-4-(methylthio)phenyl]methanone [no description available] | 2.15 | 1 | 0 | carbonyl compound; thiol | |
| GS4012 free base GS4012 free base : A member of the class of pyridines that is 2-(pyridin-4-yl)ethane-1-thiol in which the thiol hydrogen is replaced by a 4-methoxyphenyl group. | 2.15 | 1 | 0 | aryl sulfide; monomethoxybenzene; pyridines | VEGF activator |
| N-[1-(4-methylphenyl)-5-benzimidazolyl]acetamide [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| 2-(4-methylanilino)-1-(4-nitrophenyl)ethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide N-(2,6-dimethylphenyl)-N(2)-(3,5-dimethylphenyl)glycinamide : An amino acid amide obtained by the formal condensation of 2,6-dimethylaniline with N-(3,5-dimethylphenyl)glycine. | 2.15 | 1 | 0 | amino acid amide; glycine derivative | |
| 2-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]pyrimidine [no description available] | 2.15 | 1 | 0 | N-arylpiperazine | |
| 1-[(3,4-dimethoxyphenyl)methyl]-4-(2,3-dimethylphenyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 4-Piperidinobenzoic acid [no description available] | 2.15 | 1 | 0 | piperidines | |
| 1-(2-methoxyphenyl)-4-(3-thiophenylmethyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-(1-methyl-2,3-dihydropyrrolo[2,3-b]quinolin-4-yl)-2-(1-pyrrolidinyl)acetamide [no description available] | 2.15 | 1 | 0 | pyrroloquinoline | |
| 4-[(1H-benzimidazol-2-ylthio)methyl]-2-thiazolamine [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| 4-[(4-phenyl-2-thiazolyl)amino]benzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| N-[7-(1-oxopropyl)-2,3-dihydro-1,4-benzodioxin-6-yl]benzamide [no description available] | 2.15 | 1 | 0 | benzodioxine | |
| N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine: an SK channel inhibitor | 2.15 | 1 | 0 | ||
| 8-(3,5-dimethyl-1-pyrazolyl)quinoline [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2'-nitroflavone 2'-nitroflavone: has antineoplastic activity | 2.15 | 1 | 0 | ||
| N-(4-methoxyphenyl)-3,4-dihydroquinolin-2-amine [no description available] | 2.15 | 1 | 0 | aminoquinoline | |
| 1-(3-nitrophenyl)-3-phenyl-2-propyn-1-one [no description available] | 2.15 | 1 | 0 | aromatic compound | |
| vrt 532 VRT 532: a CFTR potentiator; structure in first source | 2.15 | 1 | 0 | ||
| 4-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-2-methoxyphenol [no description available] | 2.15 | 1 | 0 | piperazines | |
| 1-piperonylpiperidine 1-piperonylpiperidine: an AMPA receptor modulator; structure in first source | 2.15 | 1 | 0 | ||
| 2-[(3-fluorophenyl)methyl-(phenylmethyl)amino]ethanol [no description available] | 2.15 | 1 | 0 | aromatic amine | |
| 2-methoxy-4-[[2-(methylthio)anilino]methyl]phenol [no description available] | 2.15 | 1 | 0 | aromatic amine | |
| 6-ethyl-5-methyl-2-thiophen-2-yl-1H-pyrazolo[1,5-a]pyrimidin-7-one [no description available] | 2.15 | 1 | 0 | pyrazolopyrimidine | |
| N-[4-(2-methyl-4-thiazolyl)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(6-phenyl-5-imidazo[2,1-b]thiazolyl)benzamide [no description available] | 2.15 | 1 | 0 | imidazoles | |
| 2-(phenylmethylthio)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 5-methyl-N-(4,5,6-trimethyl-2-pyrimidinyl)-1,3-benzoxazol-2-amine [no description available] | 2.15 | 1 | 0 | benzoxazole | |
| 1-(4-methoxyphenyl)-3-(6-methyl-2-pyridinyl)urea [no description available] | 2.15 | 1 | 0 | ureas | |
| 2-{[hydroxy(2-methoxyphenyl)methylidene]amino}acetic acid [no description available] | 2.15 | 1 | 0 | N-acylglycine | |
| (4-methoxyphenyl)-(3-methyl-2-propyl-4-imidazolyl)methanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(3-acetamidophenyl)-2-chlorobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N4,N4-dimethyl-N1-(4-nitro-1,1-dioxo-2,5-dihydrothiophen-3-yl)benzene-1,4-diamine [no description available] | 2.15 | 1 | 0 | dialkylarylamine; tertiary amino compound | |
| 2-bromo-N-(3-methoxyphenyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol [no description available] | 2.15 | 1 | 0 | aromatic ether; C-nitro compound | |
| 3-[[(2,5-dimethyl-3-furanyl)-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 1-(4-ethoxyphenyl)-3-(6-quinoxalinyl)urea [no description available] | 2.15 | 1 | 0 | quinoxaline derivative | |
| 2-(dimethylsulfamoylamino)-9H-fluorene [no description available] | 2.15 | 1 | 0 | fluorenes | |
| 4-chloro-1-ethyl-3-nitro-2-quinolinone [no description available] | 2.15 | 1 | 0 | nitro compound; quinolines | |
| 4-chloro-3-nitro-1-(phenylmethyl)-2-quinolinone [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2,5-dimethyl-1-(phenylmethyl)pyrrole-3,4-dicarboxaldehyde [no description available] | 2.15 | 1 | 0 | arenecarbaldehyde | |
| 2-(2-chloro-6-fluorophenyl)-1-(2,4-dihydroxyphenyl)ethanone [no description available] | 2.15 | 1 | 0 | stilbenoid | |
| 4-methyl-N-(3-nitrophenyl)-5-phenyl-3-thiophenecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2,2,2-trichloroacetamide [no description available] | 2.15 | 1 | 0 | triazoles | |
| N-(2-fluoro-5-methylphenyl)-3-phenylpropanamide [no description available] | 2.15 | 1 | 0 | anilide | |
| N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamide [no description available] | 2.15 | 1 | 0 | organofluorine compound | |
| 4-tert-butyl-N-(1,4-dioxo-2,3-dihydrophthalazin-5-yl)benzamide [no description available] | 2.15 | 1 | 0 | phthalazines | |
| N-[2-(2-methylpropyl)-1,3-dioxo-5-isoindolyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | phthalimides | |
| 6-(1,4,5,7-tetramethyl-6-pyrrolo[3,4-d]pyridazinyl)quinoline [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2-(3,4-dimethoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone [no description available] | 2.15 | 1 | 0 | stilbenoid | |
| 5-(3-chloro-4-methylphenyl)-3-pyridin-4-yl-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | oxadiazole; ring assembly | |
| 5-(phenylmethyl)-3-(2-pyridinyl)-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | pyridines | |
| 2-methyl-5-(1-pyrrolidinyl)isoindole-1,3-dione [no description available] | 2.15 | 1 | 0 | phthalimides | |
| (2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-(4-bromo-2-fluorophenyl)-2-methyl-3-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 6,7,8,9-tetrahydro-5H-carbazole-3-carbohydrazide [no description available] | 2.15 | 1 | 0 | carbazoles | |
| N-(3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-2-pyrazinecarboxamide [no description available] | 2.15 | 1 | 0 | primary carboxamide; pyrazines; secondary carboxamide | |
| N-(1,3-benzodioxol-5-yl)-5-methyl-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | benzodioxoles | |
| 1-cyclohexyl-3-(2,3-dihydro-1,4-benzodioxin-6-yl)urea [no description available] | 2.15 | 1 | 0 | benzodioxine | |
| 8-[(2-methyl-5-nitro-1,2,4-triazol-3-yl)thio]quinoline [no description available] | 2.15 | 1 | 0 | aryl sulfide | |
| 1-[2-(2-chlorophenoxy)ethyl]benzimidazole [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| 4,5-dimethyl-2-[4-(3-nitrophenyl)-2-thiazolyl]-1H-pyrazol-3-one [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 2-(4-fluoro-N-methylsulfonylanilino)-N-(3-methylphenyl)acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 1-(4-fluorophenyl)-2-(2-pyridinylthio)ethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 3-methyl-6-(1-pyrrolidinyl)-[1,2,4]triazolo[4,3-b]pyridazine [no description available] | 2.15 | 1 | 0 | triazolopyridazine | |
| N-(3-acetylphenyl)-2-thiophen-2-ylacetamide [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| oncrasin-1 oncrasin-1: an antineoplastic agent; structure in first source. oncrasin-1 : A member of the class of indoles that is 1H-indole substituted by 4-chlorobenzyl and formyl groups at positions 1 and 3, respectively. It is an anti-cancer agent that is active against lung cancer cells with K-Ras mutations. | 2.15 | 1 | 0 | arenecarbaldehyde; indoles; monochlorobenzenes | antineoplastic agent; apoptosis inducer |
| N-[2-(4-fluorophenyl)ethyl]-4-nitrobenzamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 5-(1-methyl-2-benzimidazolyl)-2-thiophenecarboxaldehyde [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-(4-anilinophenyl)-2-methylpropanamide [no description available] | 2.15 | 1 | 0 | anilide | |
| N-(2-fluorophenyl)-3-phenylpropanamide [no description available] | 2.15 | 1 | 0 | anilide | |
| 1-[(Phenylthio)acetyl]piperidine [no description available] | 2.15 | 1 | 0 | N-acylpiperidine | |
| N-(3-hydroxyphenyl)-5-methyl-3-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 3-(4-methoxyphenyl)-5-(4-methylphenyl)-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | oxadiazole; ring assembly | |
| 4-[(4-carboxy-2,6-dimethoxyphenoxy)methyl]-5-methyl-2-furancarboxylic acid [no description available] | 2.15 | 1 | 0 | trihydroxybenzoic acid | |
| 4-(4-morpholinylmethyl)-3-quinolinol [no description available] | 2.15 | 1 | 0 | quinolines | |
| 2-bromo-N-[3-(1-oxopropylamino)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 3-acetyl-2-methylbenzo[f]benzofuran-4,9-dione [no description available] | 2.15 | 1 | 0 | naphthofuran | |
| 5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; heteroarene | |
| 1-azepanyl-[4-[(phenylthio)methyl]phenyl]methanone [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-(5-ethyl-2,4-dihydroxyphenyl)-2-(2-fluorophenoxy)ethanone [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-nitrophenyl)acetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| 3,4,5-triethoxy-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-propylsulfonyl-4-(2-pyridinyl)piperazine [no description available] | 2.15 | 1 | 0 | piperazines; pyridines | |
| 2-(2-phenylethylthio)-3-pyridinecarboxylic acid [no description available] | 2.15 | 1 | 0 | aromatic carboxylic acid; pyridines | |
| 2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 2-[[anilino(oxo)methyl]amino]-N-(phenylmethyl)benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(5-acetyl-4-methyl-2-thiazolyl)-5-bromo-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | thiazoles | |
| 1-cyclohexyl-3-(3-ethylphenyl)urea [no description available] | 2.15 | 1 | 0 | ureas | |
| n-phenylpiracetam N-phenylpiracetam: structure given in first source | 2.15 | 1 | 0 | ||
| 2-[(1-methyl-5-tetrazolyl)thio]-N-(2-phenylphenyl)acetamide [no description available] | 2.15 | 1 | 0 | biphenyls | |
| N-[3-chloro-4-(1-pyrrolidinyl)phenyl]-2-nitrobenzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa. | 2.11 | 1 | 0 | aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol | anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger |
| 4-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-N-(2,6-dimethylphenyl)benzamide [no description available] | 2.15 | 1 | 0 | isoquinolines | |
| 5-(4-bromophenyl)-N-(2-methoxyphenyl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 3-[[(3,5-dichloro-4-ethoxyphenyl)-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1,4-bis(thiophen-2-ylsulfonyl)piperazine [no description available] | 2.15 | 1 | 0 | N-sulfonylpiperazine; thiophenes | |
| 2-bromo-N-[3-(1-oxobutylamino)phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-(2-fluorophenyl)-4-[(6-nitro-1,3-benzodioxol-5-yl)methyl]piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| n-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide N-(1-benzyl-4-piperidinyl)-2,4-dichlorobenzamide: inhibits the betaine-GABA transporter 1; structure in first source | 2.15 | 1 | 0 | ||
| 2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone [no description available] | 2.15 | 1 | 0 | quinazolines | |
| 1-(2,1,3-benzothiadiazol-5-yl)-3-[4-(4-morpholinyl)phenyl]urea [no description available] | 2.15 | 1 | 0 | morpholines | |
| ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate ethyl 4-{N-[(4-chlorophenyl)sulfonyl]-N-methylglycyl}piperazine-1-carboxylate : A sulfonamide in which the nitrogen carries methyl and 2-[4-(ethoxycarbonyl)piperazin-1-yl]-2-oxoethyl substituents and the sulfonyl a 4-chlorophenyl group. | 2.15 | 1 | 0 | carbamate ester; sulfonamide | |
| LSM-4563 [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| 1-(4-chloro-3-methoxyphenyl)sulfonyl-4-phenylpiperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| N-[4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-chloro-3-(1-piperidinylsulfonyl)-N-(2-thiazolyl)benzamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 1-(2,5-dimethoxyphenyl)sulfonyl-4-(phenylmethyl)piperazine [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 2-(4-methoxyphenyl)-N-[4-[(5-methyl-3-isoxazolyl)sulfamoyl]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-[4-(benzenesulfonyl)-1-piperazinyl]-2-methylquinoline [no description available] | 2.15 | 1 | 0 | piperazines; pyridines | |
| 1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone [no description available] | 2.15 | 1 | 0 | quinolines | |
| N2-phenyl-6-[[(1-phenyl-5-tetrazolyl)thio]methyl]-1,3,5-triazine-2,4-diamine [no description available] | 2.15 | 1 | 0 | tetrazoles | |
| 2-[(4,6-dimethyl-2-pyrimidinyl)thio]-N-(4,5-diphenyl-2-oxazolyl)acetamide [no description available] | 2.15 | 1 | 0 | 1,3-oxazoles | |
| 2-(4-bromophenyl)-1-[4-(2-pyridinyl)-1-piperazinyl]ethanone [no description available] | 2.15 | 1 | 0 | piperazines; pyridines | |
| 2-amino[1,3]thiazolo[4,5-d]pyrimidine-5,7-diol [no description available] | 2.15 | 1 | 0 | thiazolopyrimidine | |
| 3-[[(2-cyclohexyl-1,3-dioxo-5-isoindolyl)-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 3-[[[3-(1-azepanylsulfonyl)-4-chlorophenyl]-oxomethyl]amino]benzoic acid [no description available] | 2.15 | 1 | 0 | benzamides | |
| 2-(4-bromophenyl)-N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)acetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| 5-(1,3-benzodioxol-5-ylsulfamoyl)-2-methoxybenzoic acid [no description available] | 2.15 | 1 | 0 | methoxybenzoic acid | |
| N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-(2-chlorophenyl)-5-methyl-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-isoxazolecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N-[3-[[(4-nitrophenyl)-oxomethyl]amino]phenyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 3-methyl-1,5-dithiophen-2-ylpentane-1,5-dione [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| N-(2-methyl-1,3-benzothiazol-6-yl)-4-(4-morpholinylsulfonyl)benzamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-(dimethylsulfamoyl)-N-(4-thiophen-2-yl-2-thiazolyl)benzamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-chloro-N-[4-[(1-oxo-2-phenylethyl)amino]phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| N-(3,4-dimethoxyphenyl)-4-[(4-phenyl-1-piperazinyl)methyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| stk295900 [no description available] | 2.15 | 1 | 0 | ||
| 1-(3-chlorophenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]piperazine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 2-[4-[[4-(4-methoxyphenyl)-1-phthalazinyl]amino]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | pyridazines; ring assembly | |
| 1-(2-fluorophenyl)-3-[5-(2-fluorophenyl)-1,3,4-thiadiazol-2-yl]urea [no description available] | 2.15 | 1 | 0 | ureas | |
| N-[5-[(4-methoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| N-(1,3-benzodioxol-5-yl)-4-methyl-1-phthalazinamine [no description available] | 2.15 | 1 | 0 | phthalazines | |
| capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers. | 2.1 | 1 | 0 | capsaicinoid | non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker |
| SMER 28 SMER 28 : A member of the class of quinazolines that is quinazoline which is substituted by a prop-2-en-1-ylnitrilo group and a bromo group at positions 4 and 6, respectively. It is a modulator of mammalian autophagy. | 2.15 | 1 | 0 | organobromine compound; quinazolines; secondary amino compound | autophagy inducer |
| N-[4-(4-morpholinyl)phenyl]carbamic acid butyl ester [no description available] | 2.15 | 1 | 0 | morpholines | |
| 4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 4-(4-chlorophenoxy)-1-(1-piperidinyl)-1-butanone [no description available] | 2.15 | 1 | 0 | N-acylpiperidine | |
| N-(3-phenylpropyl)methanesulfonamide [no description available] | 2.15 | 1 | 0 | benzenes | |
| 4-acetamido-N-(2-methoxyethyl)benzamide [no description available] | 2.15 | 1 | 0 | amidobenzoic acid | |
| 2-methyl-N-(2,3,4,5,6-pentafluorophenyl)-3-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 3,4-dihydro-2H-quinolin-1-yl-(4-propoxyphenyl)methanone [no description available] | 2.15 | 1 | 0 | quinolines | |
| 5-bromo-N-(2-phenylphenyl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 2-[2-(4-chlorophenoxy)ethylthio]pyrimidine [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 3-(3-bromoanilino)-1-(5-methyl-2-furanyl)-1-propanone [no description available] | 2.15 | 1 | 0 | aralkylamine | |
| 4-[2-(4-bromo-2-chlorophenoxy)-1-oxoethyl]-1-piperazinecarboxylic acid ethyl ester [no description available] | 2.15 | 1 | 0 | piperazinecarboxylic acid | |
| 2-[2-[[3-(1,3-benzoxazol-2-yl)anilino]-oxomethyl]phenyl]benzoic acid [no description available] | 2.15 | 1 | 0 | benzamides | |
| 1-[2-(2-chlorophenoxy)ethoxy]-2-methoxy-4-methylbenzene [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| N-[4-[(4-sulfamoylphenyl)sulfamoyl]phenyl]cyclopropanecarboxamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| N-[2-(2-phenylphenoxy)ethyl]-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | biphenyls | |
| 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4h-1-benzopyran-4-one 5,6,7,8-tetrafluoro-2-(2,3,4,5,6-pentafluorophenyl)-4H-1-benzopyran-4-one: structure in first source | 2.15 | 1 | 0 | ||
| ethyldimethylaminopropyl carbodiimide 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride: structure in first source | 2.11 | 1 | 0 | ||
| tamoxifen citrate [no description available] | 2.11 | 1 | 0 | citrate salt | angiogenesis inhibitor; anticoronaviral agent |
| 2-[bis(5-methyl-2-furanyl)methyl]-6-nitrophenol [no description available] | 2.15 | 1 | 0 | nitrophenol | |
| 2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine [no description available] | 2.15 | 1 | 0 | quinazolines | |
| 2-(4-hydroxy-1,3-thiazol-2-yl)-1-phenylethan-1-one [no description available] | 2.15 | 1 | 0 | aromatic ketone | |
| Methyl(2-furoylamino)acetic acid [no description available] | 2.15 | 1 | 0 | N-acyl-amino acid | |
| 5-nitro-8-(1-pyrrolidinyl)quinoline [no description available] | 2.15 | 1 | 0 | nitro compound; quinolines | |
| 2-(3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)-N-phenylacetamide [no description available] | 2.15 | 1 | 0 | amino acid amide | |
| 2-[(4-methylphenyl)sulfonylamino]pentanoic acid [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 4,6-dimorpholino-n-(4-nitrophenyl)-1,3,5-triazin-2-amine 4,6-dimorpholino-N-(4-nitrophenyl)-1,3,5-triazin-2-amine: an mTOR activator; structure in first source | 2.15 | 1 | 0 | ||
| 1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide [no description available] | 2.15 | 1 | 0 | piperidines | |
| 1-(2,6-dimethyl-1-piperidinyl)-2-phenylethanone [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-amino-7-methyl-5-oxo-4-(2,3,4-trimethoxyphenyl)-4,6,7,8-tetrahydro-1-benzopyran-3-carbonitrile [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| 3-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-phenylpyrrolidine-2,5-dione [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 1-(4-bromophenyl)-3-(diethylamino)pyrrolidine-2,5-dione [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 4-(5,6-diphenyl-1,2,4-triazin-3-yl)morpholine [no description available] | 2.15 | 1 | 0 | dialkylarylamine; tertiary amino compound | |
| (3,5-Dimethyl-1-adamantyl)amine nitrate [no description available] | 2.15 | 1 | 0 | nitrates | |
| 1-(4-tert-butylphenoxy)-3-(1H-1,2,4-triazol-5-ylthio)-2-propanol [no description available] | 2.15 | 1 | 0 | alkylbenzene | |
| N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-2-adamantanamine [no description available] | 2.15 | 1 | 0 | N-alkylpyrrolidine | |
| 4-phenyl-N-(pyridin-4-ylmethyl)-2-butanamine [no description available] | 2.15 | 1 | 0 | aralkylamine | |
| N-(5-nitro-2-pyridinyl)cyclopropanecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 3-[(4-bromophenyl)methyl]-4-(4-methoxyanilino)-4-oxobutanoic acid [no description available] | 2.15 | 1 | 0 | anilide | |
| 3-ethyl-N-(2H-tetrazol-5-yl)-1-adamantanecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N-(4-propan-2-ylphenyl)-3-bicyclo[2.2.1]heptanecarboxamide [no description available] | 2.15 | 1 | 0 | monoterpenoid | |
| 4-chloro-N-[2-(4-nitroanilino)ethyl]benzamide [no description available] | 2.15 | 1 | 0 | carbonyl compound; organohalogen compound | |
| 2-[(2,3-dihydro-1,4-benzodioxin-6-ylamino)-oxomethyl]-1-cyclohexanecarboxylic acid [no description available] | 2.15 | 1 | 0 | benzodioxine | |
| 2,4-dichloro-6-[1-(4-morpholinyl)-3-phenylprop-2-ynyl]phenol [no description available] | 2.15 | 1 | 0 | aromatic compound | |
| 2-[[1-(4-ethoxyphenyl)-2,5-dioxo-3-pyrrolidinyl]amino]acetonitrile [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 1-ethoxy-3-(2-methoxy-4-prop-2-enylphenoxy)-2-propanol [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| 6-amino-4-(3-chlorophenyl)-3-methyl-1-(phenylmethyl)-4H-pyrano[2,3-c]pyrazole-5-carbonitrile [no description available] | 2.15 | 1 | 0 | organochlorine compound; pyranopyrazole | |
| 1-(2-chlorophenoxy)-3-(2-methyl-1-benzimidazolyl)-2-propanol [no description available] | 2.15 | 1 | 0 | benzimidazoles | |
| N-[2-furanyl-(8-hydroxy-7-quinolinyl)methyl]-2-methylpropanamide [no description available] | 2.15 | 1 | 0 | hydroxyquinoline | |
| N-(2-hydroxy-5-methylphenyl)-2-furancarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; furans | |
| 4-amino-7,8,9,10-tetrahydro-6H-pyrimido[3,4]pyrrolo[3,5-a]azepine-11-carbonitrile [no description available] | 2.15 | 1 | 0 | organic heterobicyclic compound; organonitrogen heterocyclic compound | |
| 1-(3,5-dimethylphenyl)-3-(1H-1,2,4-triazol-5-ylthio)pyrrolidine-2,5-dione [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 6-[(3,4-difluoroanilino)-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available] | 2.15 | 1 | 0 | anilide | |
| 4-[(3-cyano-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-yl)amino]-4-oxobutanoic acid [no description available] | 2.15 | 1 | 0 | organosulfur heterocyclic compound | |
| [3-methyl-4-[oxo(thiophen-2-yl)methyl]-1-piperazinyl]-thiophen-2-ylmethanone [no description available] | 2.15 | 1 | 0 | aromatic amide; thiophenes | |
| [4-(2-methoxyphenyl)-1-piperazinyl]-[4-[(phenylthio)methyl]phenyl]methanone [no description available] | 2.15 | 1 | 0 | piperazines | |
| eskazine [no description available] | 2.11 | 1 | 0 | ||
| N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; heteroarene | |
| 4-[2-nitro-5-[4-(phenylmethyl)sulfonyl-1-piperazinyl]phenyl]morpholine [no description available] | 2.15 | 1 | 0 | piperazines | |
| 5-(4-ethylsulfonyl-1-piperazinyl)-2-nitro-N-(3-pyridinylmethyl)aniline [no description available] | 2.15 | 1 | 0 | piperazines | |
| 2-[[5-[(1,3-benzothiazol-2-ylthio)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-N-[2-(4-morpholinyl)ethyl]acetamide [no description available] | 2.15 | 1 | 0 | benzothiazoles | |
| N-ethyl-N-[2-[(5-nitro-8-quinolinyl)amino]ethyl]benzenesulfonamide [no description available] | 2.15 | 1 | 0 | nitro compound; quinolines | |
| 1-(4-methoxyphenyl)-N-(4-methyl-2-pyridinyl)-5-oxo-3-pyrrolidinecarboxamide [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 3,4,5-trimethoxy-N-[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]benzamide [no description available] | 2.15 | 1 | 0 | benzamides | |
| 3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene BRL-50481 : A C-nitro compound that is benzene substituted by N,N-dimethylaminosulfonyl, methyl and nitro groups at positions 1, 2 and 5, respectively. It is a phosphodiesterase inhibitor selective for the PDE7 subtype (Ki = 180 nM). | 2.15 | 1 | 0 | C-nitro compound; sulfonamide; toluenes | bone density conservation agent; EC 3.1.4.53 (3',5'-cyclic-AMP phosphodiesterase) inhibitor; geroprotector |
| 6,3',4'-Trimethoxyflavanone [no description available] | 2.15 | 1 | 0 | ether; flavonoids | |
| 1-[4-(3-ethoxyphenoxy)butyl]imidazole [no description available] | 2.15 | 1 | 0 | aromatic ether | |
| 5-[[(1-cyclohexyl-5-tetrazolyl)thio]methyl]-3-phenyl-1,2,4-oxadiazole [no description available] | 2.15 | 1 | 0 | oxadiazole; ring assembly | |
| 2-[1-(3,4-dihydro-2H-quinolin-1-yl)-1-oxopropan-2-yl]isoindole-1,3-dione [no description available] | 2.15 | 1 | 0 | phthalimides | |
| [4-(benzenesulfonyl)-1-piperazinyl]-(1-piperidinyl)methanone [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| 3-(2,5-dioxo-1-pyrrolidinyl)-N-(2-methyl-1,3-dioxo-5-isoindolyl)benzamide [no description available] | 2.15 | 1 | 0 | amidobenzoic acid | |
| 6-[[[5-(ethylthio)-1,3,4-thiadiazol-2-yl]amino]-oxomethyl]-1-cyclohex-3-enecarboxylic acid [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| 2,5-dimethoxy-n-(quinolin-3-yl)benzenesulfonamide 2,5-dimethoxy-N-(quinolin-3-yl)benzenesulfonamide: a tissue-nonspecific alkaline phosphatase inhibitor; structure in first source | 2.15 | 1 | 0 | quinolines | |
| LSM-25805 [no description available] | 2.15 | 1 | 0 | isoindoles | |
| 4-ethoxy-N-(3-quinolinyl)benzenesulfonamide [no description available] | 2.15 | 1 | 0 | quinolines | |
| 3-chloro-N-[3-(1-imidazolyl)propyl]-6-nitro-1-benzothiophene-2-carboxamide [no description available] | 2.15 | 1 | 0 | 1-benzothiophenes | |
| nsc 727447 NSC 727447: structure in first source | 2.15 | 1 | 0 | ||
| nsc 336628 [no description available] | 2.11 | 1 | 0 | ||
| 1,3-dimethyl-8-[2-(1-pyrrolidinyl)ethylthio]-6-sulfanylidene-7H-purin-2-one [no description available] | 2.11 | 1 | 0 | oxopurine | |
| cystine [no description available] | 1.97 | 1 | 0 | ||
| 2-methoxy-N-[(4-methylphenyl)methyl]-2-phenylacetamide [no description available] | 2.15 | 1 | 0 | acetamides | |
| 2-(4-chlorophenoxy)-N-(5-nitro-2-thiazolyl)acetamide [no description available] | 2.15 | 1 | 0 | C-nitro compound; thiazoles | |
| 7-(2-methoxyphenyl)-5-phenyl-1,7-dihydrotetrazolo[1,5-a]pyrimidine [no description available] | 2.15 | 1 | 0 | methoxybenzenes | |
| N-[3-[2,5-dioxo-3-(phenylmethyl)-1-pyrrolidinyl]phenyl]acetamide [no description available] | 2.15 | 1 | 0 | pyrrolidines | |
| 3,4-dimethoxy-N-[3-(methylthio)phenyl]benzenesulfonamide [no description available] | 2.15 | 1 | 0 | sulfonamide | |
| cambinol cambinol: inhibitor of human silent information regulator 2 enzymes; structure in first source | 2.11 | 1 | 0 | ||
| nsc 117199 [no description available] | 2.11 | 1 | 0 | ||
| 3-methyl-4-nitro-N-(1H-1,2,4-triazol-5-yl)benzamide [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| sodium dodecyl sulfate Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.. sodium dodecyl sulfate : An organic sodium salt that is the sodium salt of dodecyl hydrogen sulfate. | 1.99 | 1 | 0 | organic sodium salt | detergent; protein denaturant |
| chloramine-t chloramine-T: RN given refers to unlabeled parent cpd. chloramine T : An organic sodium salt derivative of toluene-4-sulfonamide with a chloro substituent in place of an amino hydrogen. | 1.96 | 1 | 0 | organic sodium salt | allergen; antifouling biocide; disinfectant |
| 2-[(4-chlorophenyl)methylthio]-N-(2-hydroxy-5-nitrophenyl)acetamide [no description available] | 2.15 | 1 | 0 | nitrophenol | |
| 2-(4-ethoxyphenyl)-N-[3-(1-imidazolyl)propyl]-4-quinolinecarboxamide [no description available] | 2.15 | 1 | 0 | quinolines | |
| N-(4-bromophenyl)-5-methyl-4-nitro-1H-pyrazol-3-amine [no description available] | 2.15 | 1 | 0 | C-nitro compound | |
| 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2h-indol-2-one 3,3-bis(4-hydroxyphenyl)-7-methyl-1,3-dihydro-2H-indol-2-one: an estrogen receptor alpha inhibitor | 2.15 | 1 | 0 | ||
| alpha-chymotrypsin Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side. | 7.4 | 2 | 0 | ||
| naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups. | 2.03 | 1 | 0 | ||
| N-[4-[(cyclohexylamino)-oxomethyl]phenyl]-3-pyridinecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide | |
| N,N,4-trimethyl-2-[[(5-methyl-2-furanyl)-oxomethyl]amino]-5-thiazolecarboxamide [no description available] | 2.15 | 1 | 0 | aromatic amide; thiazoles | |
| ex 527 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide: structure in first source. 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide : A member of the class of carbazoles that is 2,3,4,9-tetrahydro-1H-carbazole which is substituted at position 1 by an aminocarbohyl group and at position 6 by a chlorine. | 2.15 | 1 | 0 | carbazoles; monocarboxylic acid amide; organochlorine compound | |
| bilirubin [no description available] | 1.96 | 1 | 0 | biladienes; dicarboxylic acid | antioxidant; human metabolite; mouse metabolite |
| mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities. | 2.11 | 1 | 0 | aromatic ether; phenols; xanthones | antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite |
| coumestrol Coumestrol: A daidzein derivative occurring naturally in forage crops which has some estrogenic activity.. coumestrol : A member of the class of coumestans that is coumestan with hydroxy substituents at positions 3 and 9. | 2.11 | 1 | 0 | coumestans; delta-lactone; polyphenol | anti-inflammatory agent; antioxidant; plant metabolite |
| rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis. | 2.11 | 1 | 0 | aromatic ketone; benzenetriol; chromenol; enone; methyl ketone | anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite |
| ellagic acid [no description available] | 2.11 | 1 | 0 | catechols; cyclic ketone; lactone; organic heterotetracyclic compound; polyphenol | antioxidant; EC 1.14.18.1 (tyrosinase) inhibitor; EC 2.3.1.5 (arylamine N-acetyltransferase) inhibitor; EC 2.4.1.1 (glycogen phosphorylase) inhibitor; EC 2.5.1.18 (glutathione transferase) inhibitor; EC 2.7.1.127 (inositol-trisphosphate 3-kinase) inhibitor; EC 2.7.1.151 (inositol-polyphosphate multikinase) inhibitor; EC 2.7.4.6 (nucleoside-diphosphate kinase) inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; food additive; fungal metabolite; geroprotector; plant metabolite; skin lightening agent |
| 3-[3-[(5-ethyl-[1,2,4]triazino[5,6-b]indol-3-yl)thio]propyl]-1H-benzimidazol-2-one [no description available] | 2.15 | 1 | 0 | indoles | |
| 7,8-dimethylalloxazine 7,8-dimethylalloxazine: structure. 7,8-dimethylisoalloxazine : A 7,8-dimethylbenzo[g]pteridine-2,4-dione that is isoalloxazine substituted by methyl groups at positions 7 and 8.. lumichrome : A compound showing blue fluorescence, formed by a photolysis of riboflavin in acid or neutral solution. | 2.11 | 1 | 0 | 7,8-dimethylbenzo[g]pteridine-2,4-dione | plant metabolite |
| 4-methyl-2,7-diphenyl-8H-pyrido[2,3-d]pyrimidin-5-one [no description available] | 2.15 | 1 | 0 | phenylpyridine | |
| 3-methylharman [no description available] | 2.15 | 1 | 0 | ||
| dihydrothobainone [no description available] | 2.11 | 1 | 0 | ||
| piperic acid piperinic acid: from Piper longum; structure in first source. (E,E)-piperic acid : A monocarboxylic acid that is (E)-penta-2,4-dienoic acid substituted by a 1,3-benzodioxol-5-yl group at position 5. It has been isolated from black pepper (Piper nigrum). | 2.11 | 1 | 0 | alpha,beta-unsaturated monocarboxylic acid; benzodioxoles | plant metabolite |
| abscisic acid 2-trans-abscisic acid : An abscisic acid in which the two acyclic double bonds both have trans-geometry. | 2.11 | 1 | 0 | abscisic acids | |
| radicinin radicinin: mold metabolite from plant pathogen Stemphylium radicinum; RN given refers to (2S-(2alpha,3beta,7E))-isomer; structure | 2.11 | 1 | 0 | aromatic ketone | |
| 5,6-dichloro-1H-imidazo[4,5-b]pyrazine-2-carboxylic acid [no description available] | 2.11 | 1 | 0 | imidazopyrazine | |
| 1-methyl-beta-carboline-3-carboxylic acid 1-methyl-beta-carboline-3-carboxylic acid: metabolite from cows fed with corn silage; structure in first source | 2.15 | 1 | 0 | ||
| hispanolone hispanolone: structure in first source | 2.11 | 1 | 0 | ||
| cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3. | 2.44 | 2 | 0 | cysteinium | fundamental metabolite |
| zinc(ii) tetrakis(4-carboxyphenyl)porphine zinc(II) tetrakis(4-carboxyphenyl)porphine: structure given in first source | 1.97 | 1 | 0 | ||
| zinc tetra(4-n-methylpyridyl)porphine [no description available] | 1.97 | 1 | 0 | ||
| s-nitrosocysteine S-nitrosocysteine: A sulfur-containing alkyl thionitrite that is a nitric oxide donor.. S-nitroso-L-cysteine : An L-cysteine derivative in which the sulfur atom carries a nitroso substituent. A cell-permeable low-molecular-weight nitrosothiol and nitric oxide donor. | 2.01 | 1 | 0 | L-cysteine derivative; nitrosothio compound | hematologic agent; platelet aggregation inhibitor; vasodilator agent |
| mocetinostat mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). | 1.97 | 1 | 0 | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
| methionine sulfoxide methionine sulfoxide: RN given refers to cpd without isomeric designation. L-methionine (R)-S-oxide : The (R)-oxido diastereomer of L-methionine S-oxide. | 2.42 | 2 | 0 | amino acid zwitterion; L-methionine S-oxide | Escherichia coli metabolite |
| veratridine Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal. | 2.11 | 1 | 0 | ||
| n-monoacetylcystine N-monoacetylcystine: antidote for paracetamol poisoning | 1.97 | 1 | 0 | ||
| cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV. | 2.11 | 1 | 0 | ||
| atto655 Atto655: structure in first source | 7.08 | 1 | 0 | ||
| zimelidine hydrochloride [no description available] | 2.11 | 1 | 0 | ||
| piperidines Piperidines: A family of hexahydropyridines. | 2.07 | 1 | 0 | ||
| chlortetracycline hydrochloride Alexomycin: a thiopeptide; a cyclic peptide antibiotic produced by Streptomyces arginensis isolated from the soil | 2.11 | 1 | 0 | ||
| viridicatumtoxin viridicatumtoxin: isolated from cultures of Penicillium viridicatum; RN given refers to 2'alpha,7'beta,11'abeta,12'beta-(-) isomer. viridicatumtoxin : A tetracycline-like polyketide antibiotic that is produced by several species of Penicillium and Aspergillus. | 2.11 | 1 | 0 | ||
| muramidase Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17. | 1.97 | 1 | 0 | ||
| guanosine monophosphate Guanosine Monophosphate: A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature.. guanosine 5'-monophosphate : A purine ribonucleoside 5'-monophosphate having guanine as the nucleobase. | 2.04 | 1 | 0 | guanosine 5'-phosphate; purine ribonucleoside 5'-monophosphate | biomarker; Escherichia coli metabolite; metabolite; mouse metabolite |
| guanosine ribonucleoside : Any nucleoside where the sugar component is D-ribose. | 2.04 | 1 | 0 | guanosines; purines D-ribonucleoside | fundamental metabolite |
| dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration. | 2.11 | 1 | 0 | dacarbazine | |
| sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. | 2.15 | 1 | 0 | piperazines; pyrazolopyrimidine; sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent |
| 2-methyl-4(3h)-quinazolinone 2-methyl-4(3H)-quinazolinone: from Bacillus cereus; structure given in first source | 2.15 | 1 | 0 | ||
| n(4)-desoxychlordiazepoxide N(4)-desoxychlordiazepoxide: not phototoxic; structure given in first source | 2.15 | 1 | 0 | ||
| hematein hematein: structure. hematein : An organic heterotetracyclic compound that is -6a,7-dihydrobenzo[b]indeno[1,2-d]pyran-9-one carrying four hydroxy substituents at positions 3, 4, 6a and 10. | 2.11 | 1 | 0 | ||
| 2-amino-3-hydroxyphenazine 2-amino-3-hydroxyphenazine: structure given in first source | 2.15 | 1 | 0 | ||
| 2-styrylquinazolin-4(3h)-one 2-styrylquinazolin-4(3H)-one: structure given in first source | 2.15 | 1 | 0 | ||
| 2-amino-5-iodo-6-phenyl-4-pyrimidinone [no description available] | 2.15 | 1 | 0 | ||
| quininib quininib: has antiangiogenic activity; structure in first source. quininib : A styrylquinoline that is trans-2-styrylquinoline in which the the phenyl group has been substituted at position 2 by a hydroxy group. It is an anti-angiogenic compound that exerts a dose-dependent antagonism of the cysteinyl leukotriene pathway, preferentially antagonising cysteinyl leukotriene receptor 1. The major species at pH 7.3 | 2.15 | 1 | 0 | phenols; styrylquinoline | angiogenesis inhibitor |
| bropirimine [no description available] | 2.15 | 1 | 0 | pyrimidines | |
| aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. | 2.08 | 1 | 0 | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist |
| 2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one [no description available] | 2.15 | 1 | 0 | quinazolines | |
| 2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one [no description available] | 2.15 | 1 | 0 | quinazolines | |
| formycins Formycins: Pyrazolopyrimidine ribonucleosides isolated from Nocardia interforma. They are antineoplastic antibiotics with cytostatic properties. | 2.01 | 1 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Encephalitis, Polio [description not available] | 0 | 2.06 | 1 | 0 |
| Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5) | 0 | 2.06 | 1 | 0 |
| Anemia, Fanconi [description not available] | 0 | 2.53 | 2 | 0 |
| Fanconi Anemia Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004) | 0 | 2.53 | 2 | 0 |
| Innate Inflammatory Response [description not available] | 0 | 3.01 | 4 | 0 |
| Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. | 0 | 3.01 | 4 | 0 |
| Plasmodium falciparum Malaria [description not available] | 0 | 2.1 | 1 | 0 |
| Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. | 0 | 2.1 | 1 | 0 |
| Benign Neoplasms [description not available] | 0 | 3.03 | 1 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 3.03 | 1 | 0 |
| Rheumatoid Arthritis [description not available] | 0 | 2.25 | 1 | 0 |
| Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. | 0 | 2.25 | 1 | 0 |
| Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. | 0 | 3 | 4 | 0 |
| Age-Related Memory Disorders [description not available] | 0 | 2.17 | 1 | 0 |
| Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. | 0 | 2.17 | 1 | 0 |
| Cardiometabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY. | 0 | 2.21 | 1 | 0 |
| Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. | 0 | 2.21 | 1 | 0 |
| Metabolic Syndrome A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state. | 0 | 2.21 | 1 | 0 |
| Brain Swelling [description not available] | 0 | 2.76 | 3 | 0 |
| Benign Neoplasms, Brain [description not available] | 0 | 2.08 | 1 | 0 |
| Carcinoma, Anaplastic [description not available] | 0 | 2.08 | 1 | 0 |
| Experimental Mammary Neoplasms [description not available] | 0 | 2.08 | 1 | 0 |
| Brain Edema Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6) | 0 | 2.76 | 3 | 0 |
| Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. | 0 | 2.08 | 1 | 0 |
| Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer. | 0 | 2.08 | 1 | 0 |
| Autosomal Dominant Juvenile Parkinson Disease [description not available] | 0 | 2.1 | 1 | 0 |
| Dyskinesia, Medication-Induced [description not available] | 0 | 2.1 | 1 | 0 |
| Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) | 0 | 2.1 | 1 | 0 |
| Parkinsonian Disorders A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. | 0 | 2.1 | 1 | 0 |
| Conus Medullaris Syndrome [description not available] | 0 | 2.1 | 1 | 0 |
| Cerebral Infarction, Middle Cerebral Artery [description not available] | 0 | 2.48 | 2 | 0 |
| Apoplexy [description not available] | 0 | 2.1 | 1 | 0 |
| Injury, Ischemia-Reperfusion [description not available] | 0 | 2.48 | 2 | 0 |
| Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA. | 0 | 2.48 | 2 | 0 |
| Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction. | 0 | 2.48 | 2 | 0 |
| Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810) | 0 | 2.1 | 1 | 0 |
| ALS - Amyotrophic Lateral Sclerosis [description not available] | 0 | 2.52 | 2 | 0 |
| Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94) | 0 | 2.52 | 2 | 0 |
| Acute Brain Injuries [description not available] | 0 | 2.73 | 3 | 0 |
| Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. | 0 | 2.73 | 3 | 0 |
| Cerebral Ischemia [description not available] | 0 | 2.06 | 1 | 0 |
| Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. | 0 | 2.06 | 1 | 0 |
| Cruveilhier-Baumgarten Syndrome Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS. | 0 | 2.06 | 1 | 0 |
| Cirrhosis, Liver [description not available] | 0 | 2.06 | 1 | 0 |
| Hypertension, Portal Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN. | 0 | 2.06 | 1 | 0 |
| Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. | 0 | 2.06 | 1 | 0 |
| Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) | 0 | 2.06 | 1 | 0 |
| Atherosclerotic Parkinsonism [description not available] | 0 | 2.07 | 1 | 0 |
| Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) | 0 | 2.07 | 1 | 0 |
| Deficiency, Magnesium [description not available] | 0 | 2.02 | 1 | 0 |
| Magnesium Deficiency A nutritional condition produced by a deficiency of magnesium in the diet, characterized by anorexia, nausea, vomiting, lethargy, and weakness. Symptoms are paresthesias, muscle cramps, irritability, decreased attention span, and mental confusion, possibly requiring months to appear. Deficiency of body magnesium can exist even when serum values are normal. In addition, magnesium deficiency may be organ-selective, since certain tissues become deficient before others. (Harrison's Principles of Internal Medicine, 12th ed, p1936) | 0 | 2.02 | 1 | 0 |
| Aggression Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism. | 0 | 1.96 | 1 | 0 |
| Icterus Gravis Neonatorum [description not available] | 0 | 1.96 | 1 | 0 |
| Jaundice, Neonatal Yellow discoloration of the SKIN; MUCOUS MEMBRANE; and SCLERA in the NEWBORN. It is a sign of NEONATAL HYPERBILIRUBINEMIA. Most cases are transient self-limiting (PHYSIOLOGICAL NEONATAL JAUNDICE) occurring in the first week of life, but some can be a sign of pathological disorders, particularly LIVER DISEASES. | 0 | 1.96 | 1 | 0 |
| Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. | 0 | 1.95 | 1 | 0 |
| Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. | 0 | 1.97 | 1 | 0 |